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Abstract
Positron Emission Tomography (PET) is a non-invasive biomedical imaging method which can
quantify biochemical markers as well as functional and metabolic activity in vivo. Following
image analysis, quantification can be performed using various pharmacokinetic models, or
using simplified semi-quantitative methods. There are numerous methods by which PET data
can be analysed, and outcomes which can be reported, which differ in their accuracy, stability
and specificity. The quantification of PET data, as well as the statistical procedures used to
test clinical hypotheses, leads to conclusions which may differ in their degree of correctness.
This thesis explores themes of reliability, replicability and reproducibility for PET research.
Reliability concerns the consistency and accuracy of an outcome for distinguishing between
individuals. Replicability concerns the accuracy of research conclusions, and whether they
can be obtained again using the same procedures in new studies. Reproducibility concerns
steps towards increasing the transparency of data analysis, by recording and sharing the exact
procedures used to arrive at the conclusions. Across the studies in this thesis, these themes
are detailed, expanded upon, and used in a series of methodological and applied clinical PET
studies.
In Study I, the performance of surface-based methods for normalisation and smoothing of
PET data were compared with volumetric methods for exploratory parametric analysis using
PET test-retest data measuring [11C]SCH23390 BPND in cortical regions. We replicated
previous results of decreased spread, and showed that these methods also show improved
test-retest repeatability. In Study II, using the same data we evaluated the performance
of post-reconstruction movement correction as well as automatic and manual methods for
delineation of regions of interest. We showed that motion correction improves the reliability
and repeatability of binding estimates, and that automatic methods for delineation do not
perform less well than manual methods, and appear to be more consistent.
Study III evaluated the test-retest performance of simplified ratio-based outcome measures
for quantification of translocator protein (TSPO) binding using [11C]PBR28. We showed that
these methods exhibit poor reliability, and little to no association with the gold-standard
outcome measure VT, suggesting that caution is warranted for interpretation of studies making
use of these measures.
In Study IV, diurnal and seasonal changes in the availability of the serotonin 1A receptor
and the serotonin transporter were measured across the day and year in a large sample of
healthy controls. We replicated previous findings of seasonal changes in the availability of the
serotonin 1A receptor, failed to replicate findings of seasonal changes in the availability of the
serotonin transporter, and additionally showed diurnal changes in both targets.
In Study V, the importance of reliability is discussed with reference to study design, and a
new method is presented for making approximations of the reliability for new samples. This
approach allows researchers to more effectively gauge the feasibility of new between-individual
studies before collection of any data, and to focus their efforts on research questions which
can be expected to yield more interpretable outcomes.
In Study VI, we perform a direction replication of a previous finding of a strong association
between the Self-Transcendence scale of the Temperament and Character Inventory using a
much larger sample to assess the veracity of the original findings. We showed moderate to
strong evidence for no effect relative to the the previous results, suggesting that the original
results were more likely to be either a false positive or greatly overestimated.
In Study VII, we carried out an individual-participant data meta-analysis of TSPO binding
measured using second-generation tracers in healthy controls compared with schizophrenia
and psychotic disorder patients. Contrary to the original hypothesis of increases in TSPO
binding, we showed strong evidence for decreases in TSPO in patients compared to controls in
both cortical and subcortical regions.
In Studies VIII and IX, we hypothesised that D1 receptor binding would be higher with
increasing proneness to develop psychosis and in the early stages of the disease prior to
medication exposure, respectively. In Study VIII, we showed convergent evidence of no
association between D1 receptor availability and delusional ideation in healthy controls. In
Study IX, contrary to our hypotheses, we found moderate evidence in favour of lower levels
of D1 receptor availability in the dorsolateral prefrontal cortex of first-episode drug-naive
psychosis patients compared to healthy controls.
While reliability and replicablity of previous findings were directly assessed, the theme of
reproducibility concerned our sharing the analysis code, and the data where possible, such
that all analysis steps including those which could not be adequately described in the papers
were recorded to ensure transparency, and demonstrate the correctness of our conclusions.
All of the three themes of the thesis concern efforts to improve the quality, robustness, and utility
of scientific research. For a field such as PET imaging, which is not only resource-intensive,
but also requires exposing participants to harmful radiation, it is especially important both
from a scientific as well as an ethical perspective that data are processed and analysed in a
manner which is transparent, generalisable and optimal such that they are made use of to
their full potential.
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Abbreviation Term
3D-OP-OSEM 3D-ordinary Poisson ordered subset expectation maximization
APD Absolute Percentage Difference
AD Alzheimer’s Disease
AUC Area under the curve
AIF Arterial input function
ABSS Automated blood sampling system
BF Bayes factor
BPX Binding Potential relative to X compartment
BIDS Brain imaging data structure
COV Coefficient of variation
Bavail Density of receptors available to bind in vivo
KD Dissociation constant
DVR Distribution volume ratio
EEG Electroencephalography
fX Free fraction in X compartment
FWHM Full width at half maximum
fMRI Functional Magnetic Resonance Imaging
HAB High-affinity binder
HARK Hypothesising after the results are known
IRF Impulse response function
IPD Individual participant data
ICC Intraclass correlation coefficient
KI Karolinska Institutet
LAB Low-affinity binder
MRI Magnetic Resonance Imaging
MRS Magnetic Resonance Spectroscopy
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MEG Magnetoencephalography
MCMC Markov chain monte carlo
MAB Mixed-affinity binder
MNI Montreal Neurological Institute
NHST Null hypothesis significance testing
PET Positron Emission Tomography
PCA Principal component analysis
QRP Questionable research practice
ROI Region of Interest
5-HT Serotonin
SRTM Simplified reference tissue model
SPECT Single Photon Emission Computed Tomography
SDD Smallest detectable difference
SESOI Smallest effect size of interest
SEM Standard error of measurement
SUV Standardised uptake value
SUVR SUV ratio
TCI Temperament and Character Inventory
TAC Time Activity Curve
TCM Tissue compartment model
TSPO Translocator protein
WAPI Wavelet-transform aided parametric imaging
WSCV Within-subject coefficient of variation
VX Volume of Distribution of X compartment
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Chapter 1
Introduction
The data may not contain the answer. The combination of some data and an aching
desire for an answer does not ensure that a reasonable answer can be extracted from
a given body of data.
– John W. Tukey
1.1 Positron Emission Tomography
Positron Emission Tomography (PET) is an in vivo biomedical imaging method which provides
detailed information about biochemistry as well as functional and metabolic activity. The
spatial resolution of PET is in the range of millimetres, while Magnetic Resonance Imaging
(MRI) can achieve sub-millimetre resolution. PET imaging has a temporal resolution of several
minutes to hours, while functional MRI (fMRI) can measure events of only a few seconds, and
EEG or MEG recordings can measure electrochemical changes in the brain at a millisecond
resolution1. However, while PET cannot compare to these other methods in the spatiotemporal
domain, its strengths are in its biochemical sensitivity and specifity, which are unparalleled
compared to other in vivo imaging methods. While magnetic resonance spectroscopy (MRS)
using an MRI system can detect and quantify concentrations in the millimolar (i.e. 10-3M)
range, PET has the sensitivity to detect concentrations in the picomolar (i.e. 10-12M range)2.
The specificity of PET is related to its use of radiolabelled ligands which bind to target
molecules of interest. These radioligands are designed such that they exhibit a high binding
affinity for the target molecule which is ideally several orders of magnitude greater than for
other related molecules. This means that the vast majority of the final signal should be
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attributable to the availability of the specific target of interest. For this reason, PET imaging
yields unique information from that provided by other in vivo imaging methodologies, and can
thereby answer different questions.
1.1.1 Applications
PET imaging is used in clinical diagnosis, pharmaceutical research as well as research more
broadly due to its properties of high biochemical sensitivity and specificity, as well as providing
this information with detailed spatial resolution.
Common clinical applications of PET are in oncology, cardiology, and neurology. An example
is the use of PET using radioligands targeting the β-amyloid deposition for the diagnosis of
Alzheimer’s Disease (AD). In this way, PET imaging can differentiate AD from other denemtia
syndromes whose symptoms might be similar, but whose underlying pathology is different. A
high degree of certainty can be gained from visual inspection of a measurement following even
very simplistic quantification and short measurement duration.3, as AD is associated with
greatly increased signal intensity in several regions of the brain grey matter.
In pharmaceutical research, PET is often used in microdosing4 and occupancy5 studies.
Microdosing studies involve radiolabelling the drug molecule itself and assessing its uptake
into the body, allowing researchers to determine for example whether the drug can penetrate
the blood brain barrier and enter the brain. Occupancy studies involve PET measurements
with established radioligands, before and after the administration of different doses of the drug
of interest. With these studies, researchers can determine whether the drug can bind (and
thereby block) the target of interest, and the extent to which this occurs. These estimates can
also be used to determine the degree of target occupancy associated with therepeutic effects6,
and side effects7, and thereby select appropriate doses of the drug.
In research more broadly, and in the study of the brain specifically, PET is used to answer
questions relating to brain physiology and to both psychiatric and neurological pathology. In
the study of brain physiology, PET studies can be broadly categorised into those examining 1)
the association of PET-derived outcome measures with theoretically stable attributes (such as
personality traits8 or cognitive performance9), 2) occupancy by endogenous neurotransmitter
release or depletion10–12 during or following acute behavioural13 or pharmacological14,15
interventions, or 3) changes in target concentration before and after prolonged behavioural16
or pharmacological17 interventions or simply in healthy ageing18–20. In the study of
pathology, PET studies are generally focused either on patient-control comparisons21–24, or on
examining within-individual effects following treatment and their association to reductions in
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symptoms25,26.
There are a wide variety of experimental contexts for which PET imaging can be employed,
and a diverse range of biochemical targets which can be studied owing to the extensive
range of PET radiotracers available. As such, PET allows for the quantification of numerous
physiological parameters, including neurotransmitter receptors and transporters, abnormal
deposits of proteins and peptides, blood flow and volume, protein synthesis, metabolism of
various substances, endogenous concentrations of neurotransmitters and their release, as well as
the dynamics, kinetics and distribution of various drugs. From the perspective of measurement
and study design, PET imaging is commonly used to make comparisons between individuals,
within individuals, or even to compare within-individual changes between individuals.
1.1.2 Measurement
1.1.2.1 Radiochemistry
Radiotracers for PET imaging are synthesised by incorporating a radioactive isotope, commonly
11C, 15O or 18F, into chemical molecules which bind to, or are taken up by, the target of
interest. The isotopes are first created using a cyclotron. The labelling of the molecules is
subsequently performed using precursors. This process is usually mostly automated to ensure
that synthesis is rapid in order for radioisotopes to have decayed minimally before injection.
Following quality control, the radioligand is cleared for injection. There are several important
properties of the final injected dose which are recorded. The injected radioactivity is proportional
to the number of injected atoms of the radioactive isotope, and hence to the number of tracer
molecules containing radioactive isotopes (i.e. “hot” tracer). It is typically measured in units of
megabecquerel (MBq). The injected mass is, for a given tracer compound, proportional to the
number of injected molecules. It is measured in units of micrograms (µg). The specific activity
is the ratio of the injected radioactivity to the injected mass, which is a measure of the (small)
proportion of injected tracer molecules which contain radioactive isotopes, compared to those
which do not contain radioactive isotopes, i.e. “cold” tracer. This is typically expressed in units
of megabecquerel per microgram (MBq/µg). This is similar to the molar activity, which is the
fraction of injected radioactivity to the number of moles of the compound, typically measured
in units of megabecquerel per micromolar (MBq/µmol). As such, synthesis of radiotracers
with a high specific/molar activity allows for the injected compound to consist of a sufficient
level of radioactivity, thereby ensuring sufficient count statistics during measurement in the
PET system, without requiring injection of high mass, i.e. a large number of molecules of the
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Figure 1.1: When PET radioisotopes decay, in this case carbon-11 to boron-11, a positron
(e+) and an electron neutrino (νe) are released. The positron collides with a nearby electron
(e-). This gives rise to the emission of two γ photons in approximately opposite directions.
The figure is modified from Figure 31.4.5 from OpenStax College (2016) (27), licensed under
CC BY.
cold compound which, in sufficiently large quantities, cause a small degree of blocking of the
target.
1.1.2.2 Acquisition
Radioligands are usually administered through intravenous injection. PET radioisotopes
undergo β+ decay, meaning that one of the protons in the nucleus of the parent nuclide
becomes a neutron, and a positron and a neutrino are emitted. The positron is emitted with
a specific amount of kinetic energy (positron energy) dependent on the specific radionuclide.
When this positron comes into contact with a nearby electron, usually within a millimetre of
its release, the positron and electron annihilate together, producing a pair of γ photons, which
travel in a random direction at approximately 180◦ to one another (see Figure 1.1).
These two photons travel through tissue, skull and air and eventually come into contact with
detectors mounted in a ring around the subject (see Figure 1.2 A). These detectors consist of
scintillating crystals, which emit visible light when γ particles pass through them. The crystals
are coupled to a photomultiplier tube, which generates an electric response and registers a
detection whenever the crystals scintillate. When two photons are detected simultaneously,
this is recorded as a coincidence, and it is assumed that the positron-electron annihilation
occurred at some position along the line of response between the two detectors (Figure 1.2 A
in orange).
Some of these lines of response are detected are erroneous. Some of the γ photons are scattered
by collisions with other molecules: while many of these events are not recorded due to the
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Figure 1.2: A. The simultaneous detection of two γ photons in two detectors is recorded as a
line of response between the two detectors along which it is assumed that the annihilation took
place. Small circles represent the annihilations, dashed lines represent the path of the photons,
and the coloured detectors represent the detectors at which a scintillation took place. The
orange line of response represents a correct recording, where the line of response and the path
of the photons are overlapping. The blue line of response represents a scattered event. The
purple line of response represents a random coincidence. B. The difference between 2D and 3D
PET measurement and the permitted lines of response for a given location of the annihilation.
scattered photon never being detected (i.e. there is no coincident detection), if both photons are
detected, then the line of response will be inferred incorrectly between the two detectors, called
a scattered event (Figure 1.2 A in blue). Sometimes, by chance, two γ photons which were
emitted from different annihilations will be detected simultaneously, resulting in a coincidence
detection. This leads to an incorrectly inferred line of response, called a random coincidence
(Figure 1.2 A in purple).
PET measurements can be recorded in two- or three-dimensions (see Figure 1.2 B). In 2D
measurements, only coincident detections in the same or closely neighbouring rings of detectors
(in the axial direction, i.e. head-to-toe) are recorded. PET measurements acquired in 3D have
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a much larger number of counts, which corresponds with a higher sensitivity, however they are
associated with a much higher number of both scattered and random events, and reconstruction
is more computationally intensive28,29. While PET systems were initially operated exclusively
in 2D, PET systems used in research today are mostly, if not exclusively, operated in 3D. This
is due to the relative increase in computational power, the development and application of
more sophisticated methods of reconstruction, as well as the use of sheilding to reduce random
counts arising from activity outside the field of view of the camera30.
1.1.2.3 Reconstruction
Following detection of a large number of lines of response, PET time frames can be reconstructed
using algorithms which assign coincident detections to particular voxels of the brain. This is
performed in such a way as to determine the most likely origin of each annihilation within
the duration of the given time frame. Filtered backprojection is used in studies taking place
with the HR PET system, while 3D-ordinary Poisson ordered subset expectation maximisation
(3D-OP-OSEM) is used in studies making use of the HRRT PET system31,32. While iterative
methods such as 3D-OP-OSEM may exhibit bias for frames with low numbers of counts33,34,
and are more computationally intensive35, they provide images with superior resolution, whose
outcome measures are highly correlated with those of filtered backprojection35–37.
The resolution of a PET image is its ability to spatially discriminate between different sources
of radioactivity. As such, the resolution of PET is inherently limited by several factors. First,
the number of detectors is important: with more detectors, lines of response are defined more
accurately. Secondly, the distance between the release of the photon and the annihilation with
an electron result in a degree of blurring of the image. Thirdly, the angle at which the photons
travel away from one another is not quite 180◦ due to conservation of momentum, which also
leads to blurring. Fourth, some lines of response are erroneous due to scattered events and
random coincidences, leading to noise in the reconstructed image. Following reconstruction,
and following adjustment for decay of radioactivity, a PET image is produced consisting of three
dimensional frames, for which the value assigned to each voxel is an estimated concentration
of radioactivity within the spatial confines of that voxel.
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1.1.3 Quantification
1.1.3.1 Regions of the brain
Following reconstruction, a PET image is obtained, which is a 3D image consisting of estimated
radioactivity concentrations in each 3D pixel (voxels) in the units of radioactivity per unit
volume (typically kBq/ml). Static PET images consist of one 3D image acquired over the
whole period of measurement, while dynamic PET images consist of a series of 3D PET images
acquired during different time frames. The series of radioactivity concentrations within each
voxel, or the mean radioactivity concentration within a set of voxels (referred to as a region
of interest, ROI) over time is referred to as a time activity curve (TAC). For the purpose of
defining which voxels are of anatomical interest, and which should be combined to form specific
anatomical ROIs, PET images are coregistered to anatomical T1-weighted (anatomical) MR
images acquired for the same individuals. Anatomically relevant regions of the brain can be
defined on the MR image, and resliced to the space of the PET image to define these regions.
While comparison of outcome measures in ROIs is more commonly used in PET research, when
examining effects for which there is no strong a priori regional hypothesis, or when fine-grained
regional heterogeneity of the effects is expected, exploratory spatial methods represent a useful
approach. These methods involve calculation of parameters of interest within each voxel of the
brain independently, in contrast to ROI-based approaches. They are therefore referred to as
parametric images. This approach is therefore more computationally intensive than ROI-based
approaches as there are more voxels than ROIs, but also substantially more prone to error in
calculation of the parameters of interest due to the noisy reconstruction of each individual
voxel. A further complication is that, in order to make comparisons between individuals,
the spatial positions of these voxels must be comparable. This involves transforming the
parametric image of the brain into a common set of spatial coordinates. Statistical comparisons
between individuals, groups or conditions are thereby made at each voxel of this shared spatial
coordinate system independently, although this necessitates an increased type I error rate.
Spatial smoothing is applied in order to increase the signal-to-noise ratio of the resulting
spatial parameter estimates, either prior to, or following kinetic modelling. Smoothing also
partially compensates for the problem of multiple comparisons, allowing the use of Random
Field Theory to perform familywise error rate correction at the level of clusters rather than
individual voxels38.
For parametric analysis of cortical regions, the surface-area-to-volume ratio of the grey matter
is very high. This means that three-dimensional Gaussian smoothing can lead to problems as
a large proportion of the signal within cortical voxels following smoothing can have originated
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outside of the cortical grey matter. Additionally, signal from neighbouring sulci can be
smoothed into one another, despite their being far from one another within the cortical grey
matter itself. More recently, surface-based registration and smoothing methods have been
developed, by which values are first sampled from the centre of the cortical ribbon to a
cortical surface, following which registration and smoothing are performed using only these
values in two dimensions39,40. In this way, all signal originates in cortical grey matter, and
registration and smoothing are based on cortical folding patterns, and are thus able to be more
anatomically precise than volumetric methods allow. It was shown by Greve et al. (2014)40
that surface-based registration and smoothing led to greatly reduced intersubject variance
and bias, and could allow for greater statistical sensitivity in applied clinical studies using
parametric analysis.
1.1.3.2 Kinetic Modelling
From a TACs describing the time course of radioactivity concentration in the ROI, researchers
usually seek to derive scalar estimates describing the concentration of the target of interest (or
some proxy thereof) based on all of these values. Quantification of these outcome measures
involves comparing the radioactivity concentration in the target with a reference radioactivity
concentration such as the arterial plasma (such as the total volume of distribution, VT) or a
reference region (such as binding potential relative to the non-displaceable compartment, BPND)
of the brain using a kinetic model. Alternatively, the radioactivity in the target of interest can
be compared with the injected radioactivity per unit body mass, or the background signal
during the course of measurement for semi-quantitative estimates such as the standardised
uptake value (SUV).
The objective of kinetic modelling is to derive an analytical expression which describes the
measured TAC, and to use this mathematical description to estimate outcome measures which
describe the concentration of the target in the given anatomical location, or to describe the
behaviour of the radiotracer in the tissue. These outcome measures can then be statistically
compared between individuals, groups or conditions for a given region of the brain.
Compartmental models are the classical form of kinetic modelling. This means that the
concentration of the radiotracer within the target tissue and the reference input function
(whether it may be brain tissue or arterial plasma) are described according to compartments
between which the radiotracer can be transferred. The transfer between compartments is
described using rate constants. Models making use of the metabolite-corrected arterial plasma
as input function (shortened to the arterial input function, AIF) or are based on the three-tissue
18
Figure 1.3: For both panels, C represents the radioactivity concentrations within each
compartment. The red cylinder on the left of each panel represents the artery, containing
plasma (P). Within the plasma, the radiotracer is either free (FP), or bound to plasma proteins
(PP). The black boxes represent the compartments. TCM refers to Tissue Compartment Model.
A. The three tissue compartment model is the basis for the two- and one-tissue compartment
models: transfer between certain compartments are assumed to be sufficiently rapid that they
can be considered as single compartments for the two- and one-tissue compartment models
(coloured boxes). The compartments include FT free tracer, NS non-specifically bound, S
specifically bound, T total, and ND non-displaceable. B. Reference region models consider the
total concentration of radiotracer in the target T and in the reference region R, and assume
that the non-displaceable concentration is comparable in both regions, and that the specific
binding in the reference region is equal to 0.
compartmental model and simplifications thereof (Figure 1.3A), while models making use of
reference regions compare the concentration of radiotracer in the target and reference regions
under the assumption that the specific binding in the reference region is equal to zero, or is at
least negligible (Figure 1.3B).
Full quantification methods yield two classes of outcomes for reversible tracers: volumes of
distribution (V) and binding potential (BP). Volumes of distribution define the concentration
of the target protein in different compartments of the target tissue (VT total, VS specific,
VND non-displaceable, VNS non-specific, VFT free tracer) relative to a common reference: the
concentration of radiotracer in the arterial plasma (including that which is bound to plasma
proteins)41.
VT = VFT + VNS + VS = VND + VS
Volumes of distribution can alternatively be described in terms of rate constants as follows:
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VT =
K1
k2 (1 +
k3
k4
)
VND =
K1
k2
VS =
K1k2
k3k4
Binding potential (BP) values have in common that they are defined as the concentration
of target protein in the specifically bound compartment, relative to different reference
concentrations (BPND non-displaceable compartment, BPP plasma, or BPF the free
concentration in plasma). BP can also be conceptualised in terms of in vitro measures of
Bavail, the concentration of the available unbound target, KD, the dissociation constant, and
the free fraction in either the non-displaceable compartment (fND), or the plasma (fP)41.
BPND =
VT − VND
VND
= VS
VND
= fND
Bavail
KD
= k3
k4
BPP = VT − VND = fP Bavail
KD
= K1k2
k3k4
= VS
BPF =
VT − VND
fP
= BPP
fP
= Bavail
KD
= K1k2
fPk3k4
These are all examlples of full quantification methods: these differ from semi-quantitative
estimates in that they compare the concentration of radioactivity in tissue not just during
the course of the measurement (i.e. their area under the curve, AUC ), but their integral to
infinity, i.e.
VT =
∫∞
0 CT (t)dt∫∞
0 CP (t)dt
An example of a semi-quantitative methods is the standardised uptake value (SUV), which
makes use of the AUC during a specified time window, and compares this to a reference quantity,
in this case the ratio of the injected dose per unit body mass. Another semi-quantitative
method is the SUV ratio, which is a measure of the ratio of SUV values from two different
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Figure 1.4: The TAC can be described as the convolution of the input function with the IRF.
1TCM and 2TCM refers to the fits of the one- and two-tissue compartment models.
regions.
The instantaneous rate of change of CT can be described by flow of radiotracer to and from
the plasma, i.e. dCT (t)dt = K1CP (t) − k2CT (t). Solving the differential equation reveals that
the concentration of CT at each point in time, i.e. the TAC, can be described by a convolution
of the AIF with the impulse response function (IRF) (Figure 1.4). The IRF is the function
which describes the concentration of the radiotracer over time if the delivery of the radiotracer
were instantaneous (i.e. a Dirac delta function). The IRF therefore describes the eﬄux of the
tracer from the tissue once it is already there. The TAC can be conceptualised as resulting
from a continuous series of deliveries of the tracer over time as described by the input function,
each of which flows out of the tissue according to the IRF. In the example in Figure 1.4, after
25 minutes, only a small proportion of the tracer which arrived during the first minute after
injection remains in the tissue, while the small amount of tracer still present in the plasma at
this point is still being delivered to the tissue.
Performing blood sampling to derive an AIF can cause discomfort for research participants, is
resource-intensive due to both instrumentation and labour, and the measurements themselves
are prone to measurement error. Alternatives to blood sampling are therefore desirable.
Reference region models such as the simplified reference tissue model (SRTM)42 do not require
blood sampling, and provide estimates of BPND (for reversible tracers), provided that there
is a region of the brain with zero or negligible specific binding. BPND can be calculated by
assuming equality of VND between the target and the reference region, and by making use of
the TAC of the reference tissue as input instead of the AIF.
Fitting kinetic models to data is typically performed by using nonlinear least squares estimation,
by which rate constants describing the IRF are updated over successive iterations, and convolved
with the input function until the created TAC matches the measured TAC (i.e. it minimises
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the weighted sum of squared residuals). While these models are unbiased, they are not
guaranteed to find the optimal solution, i.e. they may arrive at a local minimum, rather than
the global minimum solution. They are also much more computationally intensive than linear
models. While computational time is barely relevant for the fitting of individual TACs, this
becomes a significant issue for the fitting of multiple TACs at the level of voxels. Furthermore,
TACs at the voxel level are usually much noisier than for ROIs, and therefore convergence
issues are more likely for nonlinear least squares estimation. For this purpose, linearisations
of kinetic models have been developed, which enable the use of linear least-squares fitting
procedures, which are much quicker, and guaranteed to arrive at the global minimum. These
models typically make use of asymptotic properties of the tissue response and provide only the
macroparameters (e.g. only VT or BPND values for invasive or non-invasive models respectively,
and not rate constants, i.e. microparameters). There exist numerous linearised models for the
fitting of data using both plasma input functions (e.g. Logan graphical analysis43) as well as
reference tissue models (e.g. the non-invasive Logan plot44). However, these models may often
provide slightly biased outcomes45, but may also reduce noise (variance) in the process.
Individual rate parameters, or microparameters, are estimated by compartmental models.
These rate constants can be compared between individuals, or used to obtain measures of
binding potential directly (e.g. BPND = k3k4 ), however this approach is prone to noise and
usually produces unreliable estimates compared to calculation of the more conservative VT46.
This is because estimation of the rate constants may often suffer from a lack of identifiability.
This means that they can not be estimated uniquely from the data, and that multiple different
combinations of values of the rate constants, which may differ considerably, can give rise to
a very similar predictions of the measured curve (Figure 1.5). The identifiability of these
outcomes is determined in part by the degree of statistical noise in the measured signal46.
There is no one optimal model or strategy for quantification of PET TAC data. Selection of the
appropriate model should be performed by taking into consideration not only the radioligand
and its kinetic behaviour, but also the results of previous test-retest evaluations, the research
question, as well as practical considerations for performing the study.
1.2 Statistical Inference
Most biomedical research is performed using the null hypothesis significance testing (NHST)
paradigm47. These approaches are referred to as frequentist as they concern themselves with
p values, which represent frequencies. In frequentist statistics, any given experiment can be
considered as one of an infinite series of possible repetitions of the same experiment, each of
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Figure 1.5: Identifiability of parameters relates to the degree to which the measured data,
i.e. the time activity curve, can be described by a unique combination of the fitted parameters.
In this figure, a single time activity curve from the same region from three individuals (rows)
was fitted using a grid of 30 parameter values for each of the four rate constants, and the
weighted sum of square residuals was calculated for each fit (i.e. the cost function). Each
point represents the value of the best fit based on the other two rate constants for the specific
combination of the rate constants represented by the x and y axes. In each case, the minimum
is represented by a red cross. It is clear that several combinations of rate constants are
associated with similar values of the cost function, implying that the goodness of their specific
fit to the measured data is similar, and that identifiability of the individual rate constants is
poor: some more poor than others. Notably, the relationships between the parameters appears
to be somewhat more identifiable than for the individual rate constants themselves, and more
so for VND (left) than for BPND (right).
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which produces a statistically independent result. The outcomes of these infinite repetitions
are calculated by what can be conceptualised as performing a simulation (or calculating the
results of such a simulation analytically given certain assumptions). This simulation concerns
what the distribution of outcomes would be if there were no effect at all in the repetitions of
the same experiment, based on the observed data which constitutes a single repetition. The p
value represents the proportion of the simulations which are more extreme than the obtained
value from the study. The significance level is defined as a reference point beyond which only
a prespecified proportion (e.g. 5%) of simulated repetitions of the experiment obtain effects
which are more extreme, despite there being no true effect. If the p value observed is more
extreme than the significance level, then it is deemed sufficiently incompatible with the null
hypothesis. This approach is referred to as “proof by contradiction”48,49.
The Fisherian approach uses the p value to assess how surprising the outcome is under the
assumption of the null hypothesis being true. Smaller p values are therefore interpreted as
being more surprising. The crux of the Neyman-Pearson approach is to define an alternative
hypothesis and to frame the interpretation of p values in terms of error rates47–49. In the latter
approach, the outcome of the experiment is dichotomised into rejecting or failing to reject the
null hypothesis based on whether the p value is above or below a prespecified threshold. This
means that the specific p value obtained is irrelevant, but that only whether it is above or
below the threshold is considered50. As described before, based on the long-run (imaginary, or
simulated) frequencies, the null hypothesis will be rejected 5% of the time when it is in fact
true. This is referred to as a Type I error, i.e. a false positive. These errors are controlled
by defining a Type I error rate, called α. The other type of error is defined as Type II error,
i.e. a false negative. The type II error rate (β) is therefore the rate of failing to reject the null
hypothesis when the null hypothesis is in fact false. This can alternatively be conceptualised
as power: the rate of successfully rejecting the null hypothesis when the null hypothesis is
false, i.e. 1− β. The power of an experiment is a function of the sample size and the the true
underlying size of the effect (Figure 1.6). Because the latter quantity cannot be known, power
analysis, and thereby sample size determination, is usually performed based on an estimated
effect size. A disadvantage of this approach is that optimistic effect size estimates lead to
optimistic estimates of power. An alternative, better strategy is to perform a study which
has sufficient power to detect the smallest effect size of interest, such that for all interesting
underlying true effect sizes, the null hypothesis will be reliably rejected51.
This approach is not intuitive, and misinterpretations of p values are common52, even by
statisticians53. This has even prompted the American Statistical Association to issue a
statement urging scientists not to simply rely on whether such a summary statistic passes a
given threshold, but to take results in greater context54. Common misconceptions about p
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Figure 1.6: Power is a function of the true underlying effect size and the sample size. In
the upper row, the observed effect sizes obtained by simulation are shown by the histogram,
with the underlying, true, effect size depicted by the blue line. The width of the observed
effect size distribution is a function of the sample size i.e. larger samples yield effect size
estimates with lower variability. The transparent red region depicts those outcomes which are
statistically significant. The power represents the proportion of the observed effect sizes which
are significant, i.e. for 50% power, 50% of the observed effect sizes will be significant, but the
other 50% are not significant due to type II error. For 0% power, i.e. the null hypothesis is
true, 5% of the effect sizes are statistically significant due to type I error. In the lower row,
the distribution of the likelihood of the resulting p values is shown, with dots depicting the
relative likelihood of obtaining p values equal to 0.001 and 0.050. For 0% power, i.e. no effect,
these values are equally likely and 5% of the effect sizes will be significant. For true effects,
i.e. power>0%, p values of 0.001 are more likely to be observed than p values of 0.050 by the
following margins: 4× for 20%, 13× for 50%, and 41× for 80% power.
values include the inverse probability fallacy (the belief that the p value indicates the probability
that the null hypothesis is true), the replication fallacy (the belief that the p value reflects
the replicability of a result), the effect size fallacy (the belief that the p value provides direct
information about the effect size) and the clinical or practical significance fallacy (the belief
that the p value relates to the importance of an effect size)52,55. It has also been suggested
that a source of the misinterpretation of p values is that the inverse probability fallacy reflects
the question that we, as scientists, are typically asking, i.e. what is the probability that the
alternative hypothesis (i.e. often our research hypothesis) is true56? Following the growing
concern around the replicability crisis in psychology and biomedical science57–62, there have
recently been suggestions to lower the default alpha threshold63, not to rely on default alpha
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thresholds64, or even to abandon significance testing entirely65.
Another issue is that of the null hypothesis: as described, a p value permits concluding either
to reject the null hypothesis or to fail to reject the null hypothesis due to insufficient evidence.
This leaves no room for being able to accept the null hypothesis, i.e. to say that there is no
effect. However, when it is important for scientists to be able to conclude that a meaningful
effect is absent, making this conclusion based on a nonsignificant p value is neither satisfactory
nor statistically valid, although the practice is common66.
There do, however, exist several approaches which can assess the null hypothesis in a statistically
valid manner. I will describe two of these approaches which are utilised in this thesis. Within
the frequentist tradition, equivalence testing involves defining a smallest effect size of interest
(SESOI) as opposed to using a point estimate null hypothesis of zero67,68. The procedure can
internally be as straightforward as performing two one-sided t tests against the SESOI bounds.
This method thereby inverts the null hypothesis, and can reject a new null hypothesis that the
effect size is larger than these bounds. Another alternative is the use of Bayesian statistics,
which, due to defining prior probability distributions over each of the parameters of the model,
is able to provide more nuanced conclusions than frequentist methods are usually capable of
inferring.
In Bayesian statistics parameters are described by probability distributions over potential
values. In this way, they differ from frequentist methods which concern themselves with the
long-run frequencies of observing certain outcomes. Rather, with Bayesian statistics, inference
can be performed with reference to the probabilities of parameters falling within certain
ranges, or by comparing the relative likelihood of the data arising under two or more different
hypotheses.
Broadly, Bayes’ rule defines the optimal manner by which beliefs can be updated given new
data69,70. In practice, when applying Bayesian inference, Bayes’ rule allows for conversion
between the probability of the data (D), and the probability of the parameters (θ) under
certain circumstances.
P (θ|D)︸ ︷︷ ︸
Posterior
=
Prior︷ ︸︸ ︷
P (θ)×
Likelihood︷ ︸︸ ︷
P (D|θ)
P (D)︸ ︷︷ ︸
Marginal
likelihood
(1.1)
This is useful, as it allows for describing the likelihood of a set of parameters conditional on
(meaning given) the data (i.e. P (θ|D), the posterior), or for describing the likelihood of the
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data conditional on a set of parameters (i.e. P (D|θ), the likelihood). Bayesian modelling
concerns itself with the posterior probability, while frequentist statistics concerns itself with
the likelihood.
In order to be able to calculate the posterior from the likelihood, a prior distribution must be
defined over the parameter values. This is occasionally viewed as a drawback, as it necessitates
an increased degree of subjectivity. However, this can also be viewed as a strength, as we
almost always have at least some knowledge about what values of the parameter are reasonable
and unreasonable.
Inference in Bayesian statistics can take several different forms. Parameter estimation refers
to examination of the posterior probability distribution for any the parameters, summarising it
by its mean value and credible intervals. In this way, as described before, we can describe the
interval in which there is a given percentage probability that the true parameter lies, given our
prior beliefs and the new data by which to update those beliefs. Similarly, we can calculate
the probability that a given parameter is above or below a certain value such as zero (called
a posterior p value). Bayesian hypothesis testing is another alternative, by which multiple
hypotheses (H), described by models, are compared. The outcome of these tests is the Bayes
Factor (BF) (equation 1.2).
P (H1|D)
P (H2|D)︸ ︷︷ ︸
Posterior
model odds
= (P (D|H1)
P (D|H2)︸ ︷︷ ︸
Bayes factor
P (H1)
P (H2)︸ ︷︷ ︸
Prior
model odds
(1.2)
BFs can be interpreted in several different ways depending on the context, all of which are
correct. BF12 represents the comparison of model 1 with model 2, such that BF12>1 means
that hypothesis 1 is preferred over hypothesis 2. BFs describe the predictive adequacy of
competing models, or hypotheses, relative to one another. They can also be conceptualised as
the relative probability of the observed data under one hypothesis compared to another69,71,
i.e. BF12=5 means that the observed data are five times more likely to have occurred under
hypothesis 1 compared to hypothesis 2. The posterior odds refers to the probability of one
hypothesis relative to another, and is equal to the BF if both models were deemed to be equally
plausible a priori (i.e. equal prior model odds) (equation 1.2). As such, the BF can also be
conceptualised as the degree to which a skeptical observer can favour hypothesis 2 a priori
before they should start favouring hypothesis 1, i.e. a BF12=5 should influence an observer
who previously believed that hypothesis 2 was up to 5 times more likely than hypothesis 1, to
revise their beliefs and start to believe that hypothesis 1 is more likely than hypothesis 2. In
this way, the BF functions as a belief update factor.
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Within a Bayesian framework, the common misinterpretations made within frequentist statistics
are often the correct interpretations of similar outcomes. For instance, confidence intervals
within the frequentist paradigm do not represent the range in which there is a 95% probability
that the true value lies72 (although this misconception is widespread73), while this is the
correct interpretation of credible intervals, their Bayesian analogue. This is an example of the
inverse probability fallacy, which is not a fallacy within the Bayesian approach. Indeed Fisher
described Bayesian statistics as “inverse probability”74. Similarly, in Bayesian hypothesis
testing, one directly evaluates and compares the likelihood of different hypotheses against one
another, while frequentist methods simply evaluate whether the null can be rejected. A further
example is that of sequential testing: using frequentist statistics, researchers cannot decide
to collect more data after checking whether the results were significant without performing
correction for multiple comparisons. This is due to the use of error rates to constrain inference,
since there are more opportunities to make errors. However, re-examination of the data,
and collection until the evidence is sufficiently compelling, is of no consequence for Bayesian
methods as they make use of probability updating75.
1.3 Challenges for Biomedical Research
Before individual observations can be represented by scientific theories and thereby become
knowledge, there are significant issues which must be overcome. These issues may either
prevent scientists from gaining conclusions from observations, or worse, may mislead scientists
into drawing incorrect conclusions from their observations. In other words, these issues concern
the ‘truth’ of individual research claims themselves, and threaten the link between observations
from research and science itself. A famous, and infamous, theoretical paper by Ioannidis
(2005)76 titled Why most published research findings are false, describes how current practices
in the field of biomedical research lead to a large number of research findings which are untrue.
Based on the considerations of the paper, several corollaries are presented, defining properties
which would be expected to diminish the likelihood of truth of any given research finding.
Of these, several can be said to be of particular relevance to the field of PET research, and
especially its clinical application. These include studies being conducted with small sample
sizes, examining small effect sizes, with flexibility of analysis outcomes, and with less a priori
selection of tested relationships. It is therefore of critical importance for biomedical research,
including clinical PET research, that the following issues be taken into consideration and
addressed.
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Figure 1.7: Threats to the veracity of scientific findings can occur at numerous different points
across the hypothetico-deductive scientific method. In each case, the stage of research is
presented in black, and the threat is presented in red. The figure is based on Figure 1 of
Munafo et al. (2017) (77), licensed under CC BY.
1.3.1 Errors and Bias
There is a potential for errors and biases to occur throughout all stages of the scientific process
(Figure 1.7) which should be considered. Below, I will expand upon most of these issues and
how they relate to one another.
Low statistical power (Figure 1.7) implies that there is an insufficiently large set of data for
providing a consistent answer to the specific research question. As described before (shown
in Figure 1.6), the power is a function of the true, unknown, effect size and the sample size.
Due to the high cost of PET examinations (individual measurements can cost more than USD
10 000), and the exposure of participants to harmful radioactivity, sample sizes are usually
low. This would not be a problem if effect sizes were large (e.g. quantifying the dopamine
transporter in Parkinson’s Disease), however truly large effect sizes are unusual in psychiatric
PET studies. As such, this issue is of particular relevance for this field, and particular efforts
should be devoted to solving this issue (discussed more in the Future Perspectives chapter).
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The issue of low statistical power is not unique to PET however, and rather appears to be a
common feature of neuroscience research across numerous methodologies78, and likely to most
fields of biomedical research.
The act of analysing and interpreting data in several different ways, and settling on a method
which produces the desired or expected outcome while neglecting to report the results of the
other paths, has been likened to a garden of forking paths79,80. This has also been called
P-hacking, but it has been argued that this latter term incorrectly implies an intention to
cheat, while it is much more commonly performed unconsciously due to all of the above biases.
It has been suggested to stem in part from the inverse probability fallacy: if one interprets a p
value as the probability that the alternative hypothesis is true, then it would be less relevant
that another method produced an insignificant result. It is only by correctly interpreting p
values as error rates that it becomes clear that there have been more opportunities by which to
make errors while exploring the different paths. Similarly, publication bias refers to publishing
only ‘successful’ outcomes, and neglecting to publish those which did not show the expected
or desired result. Publication bias, in contrast to the garden of forking paths, usually refers
to entire studies. In both cases, however, neglecting to publish outcomes which were not
statistically significant results in a substantial exaggeration of the average effect size based on
the published literature (in meta-analyses for example81). In fact, with low power, only those
studies (or forking paths of the analysis) whose observed effect sizes are exaggerated compared
to the true underlying effect size will be statistically significant as can be seen from Figure 1.6.
Another related bias is that of HARKing, or hypothesising after the results are known82. Due
primarily to hindsight bias, exploratory results are often seen as more predictable than they
really were. This has also been described as just-so storytelling: finding a story to tell to
rationalise the results83. Related again to poor statistical literacy among researchers, it is
not commonly known that, in a strict Neyman-Pearson framework, p values apply exclusively
to confirmatory research (i.e. hypotheses which were predicted in advance), and cannot be
interpreted when they are used to explore the data from which effects are found (referred to as
postdiction)84. To find a hypothesis among the final results, and to present a research finding
as if this were the primary research question as predicted from the literature, leads to inflated
effect sizes and increased rates of false positives85.
The garden of forking paths, publication bias and HARKing are referred to as Questionable
Research Practices (QRPs)86. These QRPs affect the planning of new studies, which, if
they do not account for the sometimes dramatic positive bias in reported outcomes, will be
overoptimistic about the expected underlying effect sizes. This may lead to selection of small
sample sizes, and thereby low statistical power for the true underlying effect in future studies.
30
If all these practices were uncommon, then the degree of bias in the scientific literature would
not be expected to be large. Studies of QRPs within the fields of psychology86 and ecology87
reveal, however, that they are common and widespread, suggesting that the bias within the
scientific literature is likely to be severe.
While this leads us to conclude that a large proportion of the existing literature is quantitatively,
and presumably even qualitatively, biased, there are no shortage of solutions for how this
situation can be remedied in future, most of which relate to transparency, both at the stages
of reporting and even as early as study planning; and openness of analysis methods, data, and
materials77. This will be covered in more detail in later sections.
Another very recent encouraging result comes from a large-scale replication analysis of 21
social science papers published in Nature and Science between 2010 and 201588. Sample sizes
were defined such that they had 90% power to obtain an effect size of half the magnitude of
the original findings, leading to sample sizes of on average five times the original sample sizes.
While 62% of these effects replicated, what was most encouraging was a secondary analysis
in which independent groups of peers were asked to predict the results of the replications
through a prediction market before knowing the outcomes. The results of these predictions
show perfect separation of predictions for studies which did, and did not, replicate in the
correct directions, i.e. all studies which successfully replicated were predicted as being more
likely to replicate than all studies which did not successfully replicate. This means that the
replicability of research claims is unlikely to be simply random. Rather, research peers appear
to be highly capable of detecting which results are “too good to be true”88. With increasing
awareness of the above biases, and an increasing awareness that rigorous statistical training is
important, the quality of research is likely to increase.
1.4 Reliability, Replicability and Reproducibility
The work within this thesis is centred around the concepts of reliability, replicability and
reproducibility. In this section, these terms will be defined, and related to their metaphorical
imagery on the front cover.
1.4.1 Reliability
Reliability, broadly, refers to the consistency of a measurement. In PET imaging, there
are several different measures of consistency, which I will outline briefly before returning to
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reliability specifically.
1.4.1.1 Coefficient of Variation (COV)
The coefficient of variation relates the dispersion, or spread of a set of observations, as a
function of the mean value.
COV = σ
µ
(1.3)
where σ represents the standard deviation, and µ represents the mean value of the sample.
The COV is the inverse of Cohen’s D: for this reason, a reduction of the COV results in greater
power to detect an effect of a given proportional magnitude of mean difference. COV only
applies for scales with an absolute 0.
1.4.1.2 Measurement Error
Each measurement is made with an associated error. This error can be described by its
standard error (σe), which can be thought of as a standard deviation around the measured
value referring to the spread other potential measurements of the same individual. It can be
estimated from a set of measurements in which each individual is measured more than once
using the following equation from Baumgartner et al. (2018)89.
σ2e =
1
n
n∑
i=1
k∑
j=1
(yij − y¯i)2 (1.4)
where n represents the number of participants, i represents the subject number, j represents
the measurement number, k represents the number of measurements per subject, y represents
the outcome and y¯i represents the mean outcome for that subject.
1.4.1.3 Repeatability
The repeatability of an observation refers to the closeness of agreement between successive
measurements90. In the field of PET imaging, this is often described using the absolute
percentage difference (APD), or absolute variability, which relates the within-individual
changes in the outcome value to its mean.
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APD = |y2 − y1|1
2(|y1 + y2|)
(1.5)
where y represents the outcome, and the subscripts refer to the measurement number. The
average APD across the sample of test-retest measurements is usually presented to describe
the repeatability for a particular outcome. Baumgartner et al. (2018)89, however, points out
that this measure is not sufficiently sensitive to outliers whose two measures might be highly
inconsistent. Instead, the within-subject coefficient of variation (WSCV) is recommended91,
which relates the within-subject variation to the mean outcome across the group.
WSCV = σe
µ
(1.6)
This measure can easily be converted to the smallest detectable difference (SDD), or
repeatability coefficient, which describes the smallest within-individual change which could
be considered sufficiently large that it is sufficiently unlikely to occurred by chance alone
(according to a given confidence interval, e.g. using z(1−α/2)=1.96 below)89,92.
SDD =
√
2× z(1−α/2) × σe (1.7)
The WSCV and SDD are relevant for understanding the expected degree of variability within
individuals which can be expected due to random fluctuations, and can therefore be used the
gauge the feasibility of within-subject study designs.
1.4.1.4 Reliability
This leads us to reliability, which is a measure of the consistency or accuracy of an outcome
measure. Reliability, in contrast to repeatability, is defined relative to between-individual
variation. It is defined as the proportion of the total variance which is due to ‘true’
differences, as opposed to differences arising due to error (itself caused by measurement
error or within-individual differences).
reliability = σ
2
t
σ2t + σ2e
= σ
2
t
σ2tot
(1.8)
where the subscripts refer to the sources of variation: t true, e error, and tot total. As described
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in equation 1.8 and shown in figure 1.8, it represents the relative proportion of variance in
the data attributable to true differences as compared to the combination of true and error.
This can be explained by the fact that accuracy of a measurement can only be judged in
terms of the question being asked: a common stopwatch can reliably be used to compare the
times of runners completing a marathon and group them by percentiles. However, the same
stopwatch is not considered sufficiently accurate to decide which medal should be awarded to
whom at the 100m sprint in the Olympic games. When true differences between individuals
are in the order of hours, then inaccuracies in the order of a few seconds are unimportant.
Conceptualised in this way, reliablity can be treated as a measure of distinguishability of
measurements93: the ability to separate individual measurements into those which are relatively
high compared to the rest of the group, and relatively low compared to the rest of the group.
With poor reliability, the measure itself provides insufficiently accurate information to be able
to answer this question. This is metaphorically depicted in the leftmost two panels of the
front cover, in which the cats can and cannot be easily distinguished. If measurement error
(i.e. within-individual variation) is large, but the between-individual variation is much larger,
then individuals can still be meaningfully separated into those who exhibit high outcome values,
and those who have low outcome values. Similarly, even if a measure is extremely accurate, it
is still incapable of meaningfully distinguishing between individuals who all obtain the same
outcome value. As such, reliability is a relevant measure for understanding between-individual
comparisons.
There exist several different ways to estimate the reliability of measurements. Within
psychometrics (e.g. questionnaires), reliability can also be assessed from the consistency
of different item responses within the particular scale: this is referred to as internal consistency
and can be assessed using measures such as Cronbach’s α. This is not possible for PET and
for other measures where the single measurement cannot be broken down into constitutent
parts. For these measures, test-retest reliability is a more appropriate measure of reliability.
Test-retest reliability for continuous scales is typically defined using the intraclass correlation
coefficient (ICC). In measures for which there are no systematic effects of the measurement
order, such as PET test-retest studies in which individuals are each measured twice by the
same PET system and for which within-individual changes are expected to be negligible, we
use the one-way ANOVA fixed effects model94. This is the most conservative formulation of
the ICC, and is described by the following equation:
ICC = MSB −MSW
MSB + (k − 1)MSW (1.9)
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where MSB represents the between subjects mean sum of squares, MSW represents the within
subject mean sum of squares, and k represents the number of observations (usually 2). The
ICC is an approximation of the true population reliability: while true reliability can never be
negative (equation 1.8) one can obtain negative ICC values if the MSW is larger than MSB
(equation 1.9), in which case the reliability can be treated as zero.
Measures of reliability are important in order to confirm that the data is capable of
distinguishing between individuals to a sufficient degree such that comparisons can be made.
There have been several suggestions of standard values by which to judge reliability values94–98.
As will be argued in in Study V, the guidelines of Portney & Watkins (2015)98 are most
relevant for PET studies, which defined values between 0.5 and 0.75 as poor to moderate, 0.75
to 0.9 as good, and above 0.9 as sufficient for measurements used in clinical diagnosis. These
standards are comparatively conservative, but can be considered in light of the fact that an
ICC value of 0.5 means that the variance in the data due to true inter-individual variability is
equal to the variance due to measurement error: this implies that an individual obtaining a
score equal to the mean of the group could have either the highest, or the lowest, underlying
true value of the outcome in the group, however the precision with which the outcome is
measured is not such that this could be known from a single measurement (see Figure 1.8).
1.4.2 Replicability
Replicability is ultimate standard by which scientific claims can be validated: provided that
an effect is real and robust, then any competent researcher should be able to obtain the same
result using the same procedures with adequate statistical power99. In this way, replicability
refers to the degree to which the conclusions made in a scientific study can be replicated in a
new sample (or new data) using the same analysis methods. This is described in Figure 1.9,
according to which this can be instantiated through computer code, but also refers to similar
methods more broadly.
Replications can be divided into direct and conceptual replications. Direct replication refers to
repeating an experiment in such a way as to correspond as closely as possible to the original
study. The purpose of direct replication is therefore to ascertain the consistency by which an
effect can be observed. This might involve performing testing using a new sample, or using
different software by which to arrive at the results, but doing so in such a way as to adhere to
the procedures of the original study. Conceptual replications, on the other hand, refer to new
experiments to test the predictions of a particular theory. The goal of conceptual replications
is to determine the credibility of a theoretical hypothesis99.
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Figure 1.8: Relative variance due to true inter-individual variance in blue
(i.e. between-individual variability of the underlying ‘true’ values), and measurement error in
red (i.e. within-individual variability) for different ICC values depicted by their proportional
contributions to the measured variance (above) and by their density distributions showing the
size of the distributions relative to one another (below).
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Figure 1.9: Separating a scientific investigation into the constituent data on one hand, and all
the operations and analyses conducted on that data on the other, we can describe the ability
to come to the same outcome into reproducible, replicable, robust and generalisable. The
figure is based on the figure from Whitaker (2018) (100), licensed under CC BY.
Given all the challenges for biomedical research described above, as well as the replicability
crisis in psychology and biomedical science57–62, verification of published results is of great
importance for scientific progress, and the gold standard by which the veracity of published
results can be assessed is by direct replication101. It is this that I will henceforth refer to as
replicability. This is metaphorically depicted in the middle two panels of the front cover, in
which the cat will, given two samples of the PhD student’s study environment, exhibit the
same behaviour.
1.4.3 Reproducibility
Neuroimaging, including PET, data are highly complex, and have been growing in complexity
and size. Neuroimaging data contain information in different formats from different sources
arranged in different ways, and its analysis can take many forms. Collection, storage, analysis
and sharing of data and results are therefore highly idiosyncratic between or even within
groups, and communication of all steps taken through scientific publications is not always
feasible102–104. This complicates replication efforts and thereby slows scientific progress. As
the size of data sets increases, as well as their complexity, so too do their cost. As such, full
replication of scientific claims may not even be feasible for certain research questions due to
time and expense105: Peng (2011)101 therefore describes a spectrum of reproducibility, ranging
from not reproducible (publication only) through the varying degrees of reproducibility, to full
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Figure 1.10: The spectrum of reproducibility based on Peng (2011) (101).
replication as the gold standard (Figure 1.10). According to this definition, reproducibility
thereby partially accomplishes the role of a full replication, i.e. increasing the veracity of
scientific claims. In this thesis, reproducibility will be defined as varying degrees of this
spectrum, but excluding both ends.
This has led to calls for computational reproducibility as a minimum standard for assessment
of scientific claims, i.e. that researchers share analysis code and data such that all steps are
recorded, allowing an independent researcher to reproduce the results and assess their veracity
(Figure 1.9). Reproducibility allows more than the validation of reported results, but also
functions to accelerate scientific progress, as novel methods can be readily applied and extended
by other researchers using the shared code101,105,106.
Computational reproducibility also increases the potential for the detection and correction
of mistakes, which might otherwise be unrecorded if resulting from manual graphical user
interfaces. A prominent example is that of the Duke University Scandal107,108, where unrecorded
user actions during data analysis led to clinical trials in which the wrong, potentially harmful,
medications were administered to 109 cancer patients based on incorrect results. This error
arose as a result of misalignment of two columns of a spreadsheet. It was only through highly
complex reverse-engineering of the results that this could be detected, while a reproducible
analysis would have permitted rapid detection and correction of this mistake. Another notable
example was an economics paper claiming to demonstrate the effectiveness of austerity measures
in fiscal policy, which was widely cited in political debates109: “surely the most influential
economic analysis of recent years”110. The original study was not accompanied by the data
and code. Upon request, the spreadsheet was later made available, in which it was detected
that omissions, questionable statistical procedures and an error in a Microsoft Excel formula
led to a complete reversal of the reported effect111. It is therefore of great importance that
analysis code, and data if possible, are shared, and that tools and methods are developed
which allow for all steps to be reported transparently.
For this reason, in the later papers presented in this thesis, we have published the analysis
code, as well as the data where possible. For those papers for which the data is shared, this
allows reproduction of our results, and for other researchers to be able to experiment with our
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procedures both to fully understand them, as well as to apply or extend them for their own
purposes. For those papers for which the analysis code is shared, but not the data, this will at
the very least allow other researchers to see exactly how we have performed every part of the
presented analyses, and to use our same procedures. This is metaphorically depicted in the
rightmost two panels of the front cover, in which scientific results are depicted by the cat, and
all of the steps between the data (the ink pool) and the final results are visible and recorded.
1.5 Clinical Applications
The principles of reliability, replicability and reproducibility are applied in this thesis to several
research questions. Below, I will provide a brief background to each of these questions.
1.5.1 Schizophrenia
Schizophrenia has a lifetime prevalence of 0.7% in the general population112 and has a very
high degree (~80%) of heritability113. The disorder gives rise to great adversity both for
sufferers of the condition as well as their caregivers. Current pharmacological treatment is
unsatisfactory in terms of efficacy and side effects, and there is therefore a great need for
improved diagnostic and treatment strategies directed towards the pathological mechanisms of
the disease. In particular, finding both behavioural and biological markers to aid diagnosis at
a very early phase of the disorder would enable the development of preventative treatment
approaches.
The most characteristic symptoms of schizophrenia are hallucinations and delusions.
Hallucinations are false perceptions, such as hearing voices. Delusions are irrational or strange
beliefs, such as believing that others can hear one’s thoughts. Theories about schizophrenia
have traditionally considered these perceptual alterations and the formation of irrational
beliefs as separate dysfunctions, but recent models of this disorder suggest that these
experiences may be attributable to the same core deficit beginning at some of the earliest
levels of perceptual processing114.
1.5.2 Dopamine, the D1 Receptor and schizophrenia
Schizophrenia has been directly associated with dopamine for over fifty years, due primarily
to the the fact that antipsychotic drugs block dopamine receptors, that those which bind
to dopamine receptors with greater affinity were more clinically effective115, and that the
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extent of occupancy was related to drugs’ clinical effectiveness6,7. The dopamine hypothesis of
schizophrenia has evolved over these years through several iterations116. In its first iterations,
it was focused on excessive dopaminergic transmission at dopamine receptors. In its second
iteration, it came to regard the dopaminergic disturbances as being regionally specific: more
specifically striatal hyperdopaminergia and frontal hypodopaminergia. The most recent
versions of this theory posit that psychosis in schizophrenia is associated with elevations of
presynaptic striatal dopamine function as a ‘final common pathway’: there exist many causes
of schizophrenia., all of which may interact, but they all converge in striatal presynaptic
dopamine hyperfunction. These alterations in dopamine function are associated with psychosis,
rather than schizophrenia in general. The effects of this dysfunction of the dopamine system
influence evaluation of perceived stimuli through aberrant salience attribution117. This theory
therefore differs from previous conceptions primarily in its focus on presynaptic changes in
dopamine function, and in downplaying prefrontal hypodopaminergia.116. However, there has
recently been some in vivo evidence in support of cortical hypodopaminergia too118.
There has been a great deal of in vivo evidence, shown in numerous PET studies, for elevations
in presynaptic dopamine function in schizophrenia116. These studies have focused on dopamine
release following amphetamine challenge as well as presynaptic dopamine synthesis. There has
also been evidence of elevations of presynaptic dopaminergic synthesis in individuals at high
risk of developing schizophrenia, of a smaller magnitude compared to those individuals with
schizophrenia119. Furthermore, presynaptic dopamine synthesis was shown to be higher at
baseline in those who subsequently transitioned to schizophrenia compared to those who did
not120, and increased further in these individuals following the transition to schizophrenia121.
In contrast, only a few PET studies have examined the D1 receptor (D1R) in schizophrenia.
Compared with the D2R, there is a much higher concentration of D1R in the cortex122,
and the frontal, and especially the dorsolateral prefrontal, cortex is thought to be a crucial
brain region for understanding the biological basis for schizophrenia123–125. In-vivo studies
of the D1R in schizophrenia patients have yielded mixed results (Table 1.1). Initial studies
found lower126, higher127, or no difference128 in the availability of D1R in the frontal cortex
compared to healthy control subjects. This led to concerns as to whether there were systematic
differences between what was detected with the two radioligands employed in these studies
([11C]SCH23390 or [11C]NNC112). The former two research groups have both subsequently
replicated their own respective results, in a sample of chronic medicated patients129, and in
a subsample of drug naive patients130 respectively. Further, both groups examined patients
and controls using both radioligands129,131, leading both to conclude that any differences were
unlikely to be a result of differences between the two tracers. In another small sample of twin
pairs discordant for schizophrenia, Hirvonen et al. (2006)132 observed decreases in D1R binding
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Table 1.1: PET studies comparing D1-R binding in patients with schizophrenia
or schizophreniform psychosis to that of healthy control subjects
Publication SubjectsSCZ(DN)/HC Radioligand Differences
Okubo et al. 1997 17(10)/18 SCH ↓: PFC
Abi-Dargham et al. 2002 16(7)/16 NNC ↑: DLPFC
Karlsson et al. 2002 10(10)/10 SCH no sign. diff.
Hirvonen et al. 2006 9(0)/11 SCH ↓: CAU,PUT,CX
Kosaka et al. 2010 6(0)/12 both ↓: FC,ACC,TC,STR
Abi-Dargham et al. 2012 25(12) / 48 NNC ↑ (DN): DLPFC,MPFC,OFC
Poels et al. 2013 7(4)/11 SCH no sign. diff.
Study IX 18(18)/17 SCH ↓: DLPFC
SCZ=patients with schizophrenia or schizophreniform psychosis; DN=Drug
Naive; HC=healthy control subjects; NNC=[11C]NNC112; SCH=[11C]SCH23390;
PFC=prefrontal cortex; DLPFC= dorsolateral prefrontal cortex; CAU=caudate
nucleus; PUT= putamen; CX=cortical regions; FC= frontal cortex; ACC=anterior
cingulate cortex; TC=temporal cortex; STR=striatum; MPFC=medial prefrontal
cortex; OFC=orbitofrontal cortex.
in chronic, medicated schizophrenia probands compared to controls. In contrast, higher levels
were shown in monozygotic unaffected co-twins, i.e. those individuals at high genetic risk.
Of note, in studies where both drug naive and either medicated or drug free patients were
examined, the former group has shown numerically lower D1R binding126,127,130,131. This may
be explained by a reduction in D1R due to antipsychotic treatment as has been shown in
experimental studies of non-human primates (NHPs)133,134 (although see Knable et al. 1996135),
or in the case of ongoing medication, direct D1-R occupancy7,132. To avoid this confounding
factor, future investigations of differences in the availability of the D1R in schizophrenia need
to focus on the early stages of the illness, before antipsychotic treatment, or changes prior to
its onset which lead certain individuals to be more prone to psychosis than others.
Though all of the PET studies of the D1R in schizophrenia patients have been conducted with
small sample sizes, and therefore with low statistical power, a tentative interpretation of the
results is that drug-naive patients with psychosis disorders, and potentially also unmedicated
individuals at high genetic risk for schizophrenia, show higher D1R binding in frontal cortex136.
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1.5.3 Immune activation and TSPO in schizophrenia
In addition to the dopamine system, the association of schizophrenia with immune function
also has a long history starting as early as the 1930s137. Findings of elevated schizophrenia risk
for people born in the winter months138,139 led to suggestions that the disease may be a result
of immunological disturbances following prenatal viral exposure. Evidence for a role for the
immune system in the pathophysiology of schizophrenia has since accumulated from the fields
of genetics, epidemiology and immunological research140–142. Although the involvement of the
dopamine system in schizophrenia has been clearly demonstrated, the underlying mechanism by
which dopaminergic dysfunction might occur has been suggested to possibly lie in disturbances
of the glutamatergic system caused by immune function143,144. In this case, immunological
changes may precipitate the dopamine dysfunction thought to represent the “final common
pathway” for schizophrenia116.
Translocator protein (TSPO) is expressed throughout the body and brain145, but importantly
is expressed in glial cells, including microglia within the brain. Active brain disease causes
the activation of microglia, and this change in state is associated with de novo expression of
TSPO146,147. For this reason, quantification of TSPO within the brain is thought to provide an
index of microglial activation, or neuroinflammation148,149. PET imaging using tracers which
bind to TSPO is currently the most established measure of in vivo neuroinflammation150.
PET tracers for quantification of TSPO are divided into first-generation (i.e. [11C]-(R)-PK11195)
and second-generation tracers. [11C]-(R)-PK11195 exhibits a low signal-to-noise ratio151,152
due to its high lipophilicity and hence high nonspecific binding, as well as poor test-retest
reliability153,154, however it remains the most commonly used PET TSPO tracer. Concerns
regarding the low signal-to-noise ratio of this tracer led to the development of second-generation
TSPO tracers, including [11C]PBR28, [11C]DPA-713, [11C]ER176 and [18F]FEPPA among
others, which exhibit higher signal to background (i.e. BPND) ratios151,152,155, as well as
higher reliability156–159.
There have been numerous studies attempting to measure in vivo neuroinflammation in
schizophrenia using PET. The first studies made use of the [11C]PK11195160,161, indicating
increases in patients compared to controls. Following the introduction of second-generation
TSPO radiotracers, there was a diversification of results. Later studies using [11C]PK11195
with larger samples showed no differences162,163, or higher levels only in medicated patients with
no differences observed between healthy controls and antipsychotic-free patients164. Studies
using second-generation TSPO tracers, including [11C]DAA1106, [11C]PBR28, [11C]DPA-713
and [18F]FEPPA, observed no differences165–168, increases169 as well as decreases170.
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1.5.4 Delusional Ideation and Self-Transcendence
As described earlier, hallucinations and delusions are central symptoms of schizophrenia. While
psychotic patients have more of these experiences than healthy populations do, there is a wide
distribution of the number of delusional beliefs171,172 and anomalous perceptions173 held by
healthy populations. These experiences in healthy populations exhibit various properties which
suggest that they may be related to the same experiences in patients: delusional beliefs and
anomalous perceptions appear to co-vary to a large extent173, there are more of these beliefs
held by relatives of schizophrenia patients174, and these subclinical symptoms may constitute
an important risk factor for later psychosis175,176. This provides evidence both for the validity,
and of the relevance, of these behavioural dimensions for understanding psychosis itself.
Just because symptoms associated with psychosis are continuously distributed within the
general population, this does not necessarily imply that psychosis itself is not qualitatively
different from normal experience177. This necessitates careful definition of what exactly is
being referred to, and what exactly it is that lies along the continuum. It has been suggested
that psychotic experiences should be separated from true subclinical psychotic symptoms
(associated with distress and help-seeking), but even psychotic experiences have an estimated
prevalence of less than 10%176,178: these symptoms are still described as being ‘clinically
relevant’178.
The types of beliefs and experiences measured by the PDI171,172 and CAPS173 scales respectively,
are comparatively much more common, and for the most part are primarily not of clinical
relevance unless present in large numbers or associated with significant distress. Rather,
these scales are considered an index of delusional ideation and anomalous perceptions as
manifestations of a latent schizotypy which may predispose one to developing psychosis. These
measures do not represent gradations of disease, and high scores do not deterministically
produce the disease. Rather, an individual with a very high score on these scales may never
develop psychosis, but may have been more ‘prone’ to develop psychosis than another individual
who, through environmental exposure, does go on to develop psychosis. While there exists
considerable disagreement about what schizotypy truly represents179, this view is consistent
with a version of schizotypy which accepts a continuum among the general population, but
which posits that development of a psychotic episode itself is not attributable simply to an
extreme number or strength of this trait in and of itself.
As such, these scales are thought to be of utility for understanding the continuum of
psychological and/or biological processes which may underlie these symptoms in psychosis,
and have been shown to be related to various other behavioural models of psychotic
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symptoms180–182.
The Temperament and Character Inventory (TCI) is a model of the structure and development
of personality, and one of its subscales is the Self-Transcendence scale183. This scale was
created to refer to the degree to which an individual feels part of nature and the universe at
large, as well as extraordinary experiences: it is a measure of creativity and spirituality183,184.
These extraordinary experiences, however, include experiences such as exta-sensory perception,
which bears more than a passing resemblance to items from the PDI questionnaire. Indeed, it
was later found that scores on this scale were in fact associated with proneness to developing
psychosis as well as psychotic phenotypes185–190. This can be taken both to lend more evidence
for this theory of delusional ideation as psychosis proneness, but also to suggest that this scale
may, in addition to the PDI, be of relevance for understanding this trait.
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Chapter 2
Aims
The central aims of this thesis can be conceptualised in terms of proximal and distal aims.
Proximal aims
The proximal aims of this thesis are focused on advancing the ability of PET research to
answer applied clinical research questions in a manner which is as robust as possible as follows:
I Reliability: Measure and evaluate the reliability of outcome measures for answering
clinical research questions, and determine the influence of various image analytic and
methodological factors on the reliability of these measures.
II Replicability: Evaluate the correctness of published and preliminary scientific results
by replication.
III Reproducibility: Conduct research in as robust and transparent a manner as possible
to allow others to better evaluate claims, reduce the potential for errors, and increase the
ease and speed of transmission of methods and tools.
Distal aims
The distal aim of this thesis is the study and characterisation of the disturbances underlying,
and leading to the development of, schizophrenia. We examine the following:
I Dopamine system: Evaluate the hypothesis for changes in the brain dopamine system,
and the D1 receptor in particular, associated with schizophrenia and proneness for
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developing schizophrenia, using PET.
II Immune system: Evaluate the hypothesis that schizophrenia is associated with
upregulation of the immune function in the brain, using PET.
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Chapter 3
Materials and Methods
This chapter provides a general description of the methods used throughout the following
thesis.
3.1 Participants
All studies involving collection of PET data from human participants were approved by the
Regional Ethics and Radiation Safety Committee of the Karolinska Hospital, and all subjects
included in the studies provided written informed consent prior to their participation. The
thesis also includes data which was collected in other PET centres in the United Kingdom,
the United States of America and in Canada, however these data consisted only of outcome
measures from already-published studies to answer the same research question as had originally
been posed, and thereby did not require additional ethical approval or consent.
Studies I and II: The participants included in these studies consisted of sixteen healthy
control subjects, each of whom were examined twice with [11C]SCH23390. All participants
underwent a screening procedure and were deemed to be healthy with no history of significant
psychiatric or somatic illness. Participants were aged between 21.8 and 35.0 years, and all
were male.
Study III: The participants included in this study consisted of twelve healthy control subjects,
each of whom were examined twice with [11C]PBR28. The study consisted of six medium-affinity
binders (MABs) and six high-affinity binders (HABs)191–193. The mean age of participants
was 23.9 (SD 2.99), and the sample consisted of six males and six females. These individuals
are the same as those included in a previous test-retest study with this tracer158.
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Study IV: The participants included in this study consisted of healthy control subjects,
of whom 56 individuals aged between 22.0 and 55.4 years old were examined with
[11C]WAY-100635, and 40 individuals aged between 21.9 and 55.4 years old were measured
using [11C]MADAM. These individuals consisted of healthy male control subjects from
previous studies conducted within the group using the same PET system and the same
measurement and reconstruction protocols194–201.
Study V: This study did not make use of any new participants, and instead consisted of an
analysis of summary statistics from several previously published studies20,158,202,203.
Study VI: The participants included in this study are the same as those included in Study
IV who underwent PET measurements using [11C]WAY-100635 who had also completed the
Temperament and Character Inventory (TCI) scale. The final sample consisted of 50 healthy
male participants in the same age range as for Study IV.
Study VII: This study was a meta-analysis of published findings using individual participant
data (IPD). Research groups who had published studies comparing TSPO levels in schizophrenia
patients with controls using arterial blood sampling and using second-generation TSPO
PET tracers, were asked to provide VT values quantified using the two-tissue compartment
model166–170. The final sample consisted of 77 healthy controls (35 female, 56 HABs) and 75
patients with psychosis or schizophrenia (24 female, 52 HABs) aged 33.9 ± 12.6 and 35.4 ±
15.1 (mean ± SD) respectively.
Study VIII: This study consisted of four substudies conducted using data from three different
cohorts of subjects. A first cohort consisted of 132 subjects (72 female) aged between 22 and
76 who had completed psychometric questionnaires. The second cohort consisted of a cohort of
individuals who were each measured once with PET and [11C]SCH23390. Of these individuals,
27 (8 female), aged between 23 and 76, completed psychometric questionnaires at the time
of PET. Of the same cohort, those individuals who were male and between the ages of 20
and 35 at the time of PET, were contacted by letter and asked to complete an additional
psychometric questionnaire online. This sample consisted of 41 participants, who completed
the questionnaires between 4.8 and 12.7 years after their PET studies. An third cohort was
collected consisting of 20 healthy male participants aged between 22 and 35, and each measured
at least once with [11C]SCH23390 and who completed psychometric questionnaires.
Study IX: The participants included in this study consisted of 17 healthy control subjects
and 18 first-episode drug-naive psychosis patients, each of whom were measured with PET
and [11C]SCH23390. Participants were aged between 22 and 52 years.
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3.2 Magnetic Resonance Imaging Procedures
All participants in all studies underwent MRI measurements to describe the underlying brain
anatomy. In all studies but Study IX, T1-weighted MRI images were acquired for all individuals
for delineation of anatomical regions of interest. T2-weighted images were acquired for all
individuals who underwent PET at Karolinska Institutet and examined for structural pathology.
In Study IX, only T2-weighted images were acquired for some individuals, which were used for
anatomical delineation.
Three different MRI systems were used for PET measurements conducted at the Karolinska
Hospital. These include the 1.5T Siemens Magnetom Avanto system (Erlangen, Germany)
(Studies I, II, XIII), the 1.5T GE Signa system (Milwaukee, WI) (Studies IV, VI, IX), and the
3-T General Electric Discovery MR750 system (GE, Milwaukee, WI) (Study III).
3.2.1 Definition of regions of interest
In the thesis, regions of interest (ROIs) were defined using manual, automated and
semi-automated methods. Manual ROI delineation was performed using in-house
software204 in which ROIs are drawn on subsequent slices of the anatomical MR
image. Our primary method for automated delineation of ROIs was FreeSurfer (5.0.0,
http://surfer.nmr.mgh.harvard.edu/)205–208, which defines ROIs in the space of each individual
MR. Our secondary method for automated ROI delineation was the use of volumetric
normalisation methods. This involves normalising each individual brain to MNI (Montreal
Neurological Institute) space, and saving the warping parameters. Subsquently, these warping
parameters can be inverted and used to warp ROIs defined in MNI spatial coordinates back
to individual space. For the reference region in particular, we aimed not to have the most
anatomically correct region, but rather the specific areas of the anatomical reference region (in
this case the cerebellum) with the best properties for quantification. We therefore made use of
a customisation of the defined region which would exclude regions of the reference region
which were in close proximity to either the CSF or to higher-binding regions. Semi-automated
methods for ROI delineation involved the approximate delineation of ROIs, and using the
image itself to refine the delineation by selecting the voxels with the highest intensity209.
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3.3 Positron Emission Tomography Procedures
3.3.1 Radioligands and Targets
[11C]SCH23390210 was used in studies I, II, VIII and VI to measure the dopamine D1
receptor. This receptor is highly concentrated in the striatum, lower in cortical regions,
and negligible in the cerebellum122. [11C]SCH23390 binds primarily to the dopamine D1
receptor, although 5-HT2A receptor binding represents a non-negligible proportion of the
specific binding (estimated to be approximately a quarter) in cortical regions211.
[11C]PBR28212 was used in studies III and VII. This is a second-generation radiotracer for
the 18kDa translocator protein (TSPO). This target was initially described as a peripheral
benzodiazepine receptor, but it has since been shown to be expressed throughout the body and
brain145. Importantly, it is expressed in glial cells, including microglia. Active brain disease
causes the activation of microglia, and this change in state has been associated with de novo
expression of TSPO146,147. For this reason, PET tracers binding to TSPO are used as an
estimate of microglial activation, or neuroinflammation150. This radiotracer binds throughout
the brain, meaning that there is no suitable reference region213. Comparison of individuals
assessed using this tracer is complicated by the fact that the binding affinity is dependent
on a polymorphism in the gene encoding the protein191–193 which is not thought to affect
the biological function of TSPO. However, this results in differences in binding estimates:
individuals are thus described as high-affinity binders (HABs, high-affinity homozygotes),
medium-affinity binders (MABs, heterozygotes) and low-affinity binders (LABs, low-affinity
homozygotes). These differences must be accounted for during statistical analysis.
[11C]WAY-100635214 was used in studies IV and VI. This is a radiotracer for the serotonin
1A (5-HT1A) receptor, which is highly concentrated in the hippocampus and neocortex, and
which is expressed in very low quantities within the basal nuclei. Binding in the cerebellum is
low in most individuals, but exceptions have been noted, thereby complicating its use as a
reference region for quantification215,216.
[11C]MADAM217 is a radiotracer for the serotonin transporter (5-HTT), and was used in Study
IV. This tracer exhibits high binding in the striatum (especially the putamen), thalamus and
brainstem, moderate binding in the cingulate cortex and limbic cortex, low binding in the
neocortex, and very low to negligible binding in the cerebellar cortex196.
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3.3.2 Image Acquisition and Reconstruction
PET measurements which took place at the Karolinska Hospital (i.e. excluding Study VII)
were performed using two PET systems, namely the ECAT Exact HR 47 (CTI/Siemens,
Knoxville, TN), and the High Resolution Research Tomograph (HRRT) (Siemens Molecular
Imaging). These will henceforth be referred to as the HR and HRRT PET systems.
For PET images acquired using the HR, spatial resolution ranges from 3.6 mm full width half
maximum (FWHM) at the centre of the field to 4.5 mm tangentially and 7.4 mm radially at
20 cm from the centre218. Prior to each PET measurement, transmission scans were performed
using three rotating 68Ge rods in order to correct for signal attenuation. For all studies except
for Study IX, the camera was run in 3D mode. For Study IX, acquisition was performed in 2D
for most measurements. Data were reconstructed using filtered backprojection using a Hann
filter with a 2mm cutoff frequency.
For PET images acquired using the HRRT, spatial resolution ranges between 2.5mm FWHM at
the centre of the field, to 3.5 mm at 14 cm from the centre219. Prior to each PET measurement,
transmission scans were performed using a single 137Cs source. Measurements were acquired
in 3D. Reconstruction was performed using the 3D-OP-OSEM reconstruction with 16 subsets
and 10 iterations.
3.3.3 Arterial Blood Sampling
Arterial blood sampling was performed for the PET examinations in Study III. During the first
minutes of the acquisition, blood samples were acquired continuously using an automated blood
sampling system (Allogg AB, Sweden). Manual blood samples of 1-3 ml were also acquired
throughout the acquisition. Radioactivity was measured using a well counter cross-calibrated
with the PET system. Plasma samples were obtained following centrifugation of the blood.
Plasma radioactivity was measured using the same well counter, from which plasma-to-blood
ratios could be derived. The plasma parent fraction, i.e. the fraction of the unmetabolised
tracer compound in the plasma, was assessed using high performance liquid chromatography.
For obtaining metabolite-corrected arterial plasma input function curves, we first performed
dispersion correction on the blood measurements obtained using the automated blood sampling
system, and then derived blood curves using linear interpolation of the blood radioactivity
using both automated as well as manual samples. Linear interpolation was applied to measured
plasma-to-blood ratios, and this ratio was multiplied by the blood curve to obtain an estimate
of plasma radioactivity. Linear interpolation was applied to measurements of the plasma parent
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fraction, which were multiplied by the plasma concentrations to obtain metabolite-corrected
arterial plasma input function curves.
3.3.4 Kinetic Modelling and Quantification
In the majority of the quantification performed within this thesis, we made use of the simplified
reference tissue model (SRTM)42. This model makes use of nonlinear least squares estimation
to derive estimates of three parameters: R1 (the relative target to reference rate of delivery,
i.e. K1K′1 ), k2 (the eﬄux rate constant), and BPND. This model is based on four assumptions,
namely that 1. the reference region has no specific binding, 2. the kinetic behaviour of the
tracer can be represented by a one tissue compartment model (1TCM) in both the target and
reference regions, 3. the blood volume for both the target and reference regions is negligible,
and 4. that both the target and reference regions have the same VND. SRTM is described by
the following equation.
CT (t) = R1CR(t) + (k2 − R1k21 +BP targetND
)CR(t)⊗ e
− k2
1+BPtarget
ND
t
In studies for which parametric imaging was used, we made use of the 3D stationary
wavelet-transform aided parametric imaging (WAPI)220,221 employing the non-invasive Logan
plot fitted with a multilinear regression222. This model is fitted using ordinary least squares,
and requires a fixed value of k’2 (which we define as 0.1 by default), as well as a specification
of the t* (the point in time at which the fitted line becomes linear). It yields two parameters,
namely BPND and b, the latter of which can be discarded. This model is described by the
following equation.
∫ t
0
CT (τ)dτ = DV R
(∫ t
0
CR(τ)dτ +
CR(t)
k′2
)
+ bCT (t)
We made use of the two-tissue compartment model (2TCM) using metabolite-corrected arterial
plasma (AIF) for quantification of [11C]PBR28. This model makes use of nonlinear least
squares estimation to derive estimates of the rate constants K1, k2, k3 and k4, from which VT
is calculated using the following equation: VT = K1k2 (1 +
k3
k4
).
We also made use of several semi-quantitative estimates of uptake. These included the
standardised uptake value, described as SUV (t) = Cimg(t)IR/BW , where Cimg is the radioactivity
concentration in the image for a particular time frame, IR is the injected dose of radioactivity,
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and BW is the bodyweight. This measure is therefore an index of the tracer uptake relative
to the injected dose per unit body mass. This measure is usually calculated as the AUC for
a particular time interval. We also employed ratio methods: the SUV ratio (SUVR) and
the distribution volume ratio (DVR), which are ratios of SUV and VT values in the target
compared to a reference region.
3.4 Questionnaires
In studies VI and VIII, we make use of questionnaires. In Study VIII, we made use of the
21-item version of Peters Delusion Inventory (PDI)171,172. In both studies, we made use of the
Temperament and Character Inventory (TCI)183, translated into Swedish223. In Study VI, we
made use of the self-transcendence scale and its spiritual acceptance subscale. In Study VIII,
we made use of the same scale, but selected only a subset of items to define an instrument
for the measurement of delusional ideation specifically, rather than self-transcendence. We
performed psychometric validation of these items, and derived a novel scale for this construct
which showed acceptable reliability and convergent validity.
3.5 Statistical Analysis
In studies II, IV, VI, VIII and IX, we made use of various classic forms of linear regression
including correlations, multiple linear regression, t-tests and two-way ANOVA, using p values
to draw inferences. Additionally in Study I, we made use of non-parametric Mann-Whitney U
Tests since normality of residuals could not be assumed. In the exploratory analysis of Study
XIII, we performed a multiverse analysis224, since we could not define a favoured analysis
method a priori. This means that the results were transparently presented following each
potential analysis decision, i.e. along each path of the “garden of forking paths”.
We also used principal components analysis (PCA) in Study III for dimension reduction in
order to examine the correlational structure of the data. Distributions were represented
using histograms, kernel density estimation displayed in density plots and violin plots.
Two-dimensional kernel density estimations were also represented by colour in scatter plots in
Study I.
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3.5.1 Bayesian Analysis
We used Bayesian methods to perform both hypothesis testing (Studies VI-IX) as well as
parameter estimation (Study VIII). Bayesian model fitting was performed both using analytical
solutions using JASP225, as well as using Markov Chain Monte Carlo (MCMC) using the
Gibbs sampler JAGS226, as well as the Hamiltonian Monte Carlo sampler STAN 227 (the latter
performed using the brms interface228) called from R229. In studies making use of Bayesian
hypothesis testing, we made use of Bayes Factors (BFs), comparing the average likelihood of
the alternative hypothesis to the (nested) null hypothesis, using the Savage-Dickey ratio230.
We made use of both regularising and informative priors. Regularising priors are centred at zero
and decrease in probability with more extreme values. We made use of normal distributions,
for which the standard deviation is equal to the size of the tested effect: this means that 68%
of the prior probability density is allocated to effect sizes smaller than the tested effect size,
and only 5% of the probability density to effect sizes more than twice as large, based on the
recommendation of Dienes (2014)231.
Informative priors were defined for accounting for the effects of confounders, and specifically
the effects of age. In most studies in this thesis, age is expected to have a a non-negligible
effect on various outcome parameters. However, in the examined data, neither the age ranges
nor the sample sizes are large, which might have allowed us to accurately assess the effects of
age. Rather, we can see that there appears to be an effect, but deriving an accurate estimation
of its magnitude based on our data is not possible. The usual solution would be to add age
to the regression model and hope that it is relatively accurately estimated. However, using
Bayesian modelling, we can define an informative prior over the expected degree to which age
is expected to affect the measured values, and then update this estimate based on our data.
This both corrects for the effects of age, as well as constrains this correction to reasonable
values of the relationship based on previous studies using larger samples and wider age ranges.
Informative priors were also used in this thesis in the studies which involved a replication,
or more specially, made use of replication BFs232–234. These tests evaluate the success of a
replication attempt by defining the results of an initial study as a posterior distribution. This
posterior distribution is utilised as a prior for the parameter of interest in the replication
attempt, and the BF is calculated using a Savage-Dickey ratio. In so doing, the replication
BF compares a skeptic’s null hypothesis with the proponent’s initial results, including their
uncertainty. The replication BF can broadly be interpreted as a measure of how much support
there is in data for a successful replication relative to a failed replication. Alternatively, it
can be formulated as the relative likelihood of the new data originating under each of the two
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hypotheses, or as the relative change in the likelihood of the estimated effect being equal to 0
before, and after, having observed the data from the replication study.
Linear mixed effects modelling (multilevel modelling) was employed in the meta-analysis. Such
models allow for the specification of a hierarchical structure of data to exploit similarities
between data belonging to different clusters, thereby leading to improved estimates and
predictions235. Multilevel modelling has been applied in numerous fields of research, and has
been argued to be a more sensible default method by which statistical inference should be
performed in general236.
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Chapter 4
Results and Discussion
In this section, I will outline the relevant results and conclusions from each study, describe
how the themes are represented by each study, and follow this with a transparency statement
for certain studies.
4.1 Study I: Reliability of volumetric and surface-based
normalisation and smoothing techniques
In neuroimaging, the conventional approach for parametric analysis is to apply normalisation
and smoothing procedures in three dimensions. However, due to the high surface-area-to-volume
ratio in the cortex, volumetric (three-dimensional) methods entail that values originating in
voxels belonging to different tissue types are averaged together. Surface-based (two-dimensional)
methods were proposed as an alternative approach which would be expected to minimise this
issue for cortical regions39, and it was subsequently shown that this method greatly reduced
intersubject variance and bias in PET data acquired using an HRRT PET system using
[11C]SB20714540.
In this study, we aimed to extend these findings to determine whether they were also reflective
of improved test-retest repeatability and reliability. In the previous study, kinetic modelling
was always performed after smoothing, however our group has shown excellent performance
of a wavelet-based method for noise reduction (wavelet-transform aided parametric imaging,
WAPI)220,221 which performs minimal smoothing while enhancing signal-to-noise ratio. We
therefore also aimed to explore whether kinetic modelling performed before or after smoothing
could rescue the performance of volumetric methods, or further improve the performance of
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surface-based methods.
We found that surface-based methods produced higher BPND values, with less dispersion
(coefficient of variation, COV) and with less bias. For the comparison of test and retest
outcomes, we showed that surface-based methods improved repeatability, and decreased
measurement error (SEM). However, we found that surface-based methods exhibited lower
reliability (Figure 4.1).
Due to the fact that reliability values appeared to show an advantage for volumetric methods in
contrast to all other tested metrics, we examined this outcome in more detail. By comparing the
reliability (ICC) with other outcomes at the level of individual voxels, we discovered that those
voxels for which the ICC was highest for volumetric methods, were also the voxels with poor
repeatability, high bias and negative BPND (Figure 4.2). Of the voxels with ICC>0.75 using an
8mm volumetric smoothing kernel, 44% had an APD>90%, and 42% had BPND<0. Using the
comparable surface-based smoothing kernel using dynamic data, only 13% had an APD>90%,
and 1.3% had BPND<0. This means that the apparent improvement in reliablity for volumetric
methods is likely to be artefactual. Further, this means that volumetric normalisation and
smoothing methods are inducing systematic differences between individuals, presumably as a
result of subtle differences in anatomy.
We additionally showed that the use of WAPI was not sufficient to cause volumetric methods
to exhibit similar performance to surface-based methods. Further, for surface-based methods
we showed that with a small degree of smoothing, modelling BPND using WAPI prior
to smoothing caused improvements over modelling BPND after smoothing, but that this
improvement disappeared and even reversed with larger smoothing kernels, suggesting that
the less computationally-demanding surface-based smoothing method can be used for noise
reduction instead of the more computationally expensive WAPI method, provided that the
degree of smoothing is sufficient.
In conclusion, we show that surface-based methods for normalisation and smoothing appear
not only to improve the spread and result in higher BPND values as previously reported,
but also improve test-retest performance. Although reliability appeared to be increased for
volumetric methods, we showed that this reflected systematic bias in BPND. This bias, due to
its non-stochastic nature, is likely to increase the possibility of false positives in applied studies,
especially in studies of patient groups who are known to exhibit anatomical differences. These
improvements in performance using surface-based methods were calculated to correspond with
the need for a sample size of approximately half the size to detect a difference between groups
of a given magnitude compared to using volumetric methods.
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Figure 4.1: Comparison of voxel/vertex-wise test-retest value metrics for each method tested.
Points in the centres of distributions represent medians. Values beyond the y axis limits have
been truncated to be equal to the axis limit value in order to visualise the entire distribution
of values.
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Figure 4.2: Comparison of voxel/vertex-wise ICC values and APD, Bias and BPND. Colours
represent relative two-dimensional density estimates. Values beyond the axis limits have been
truncated to be equal to the axis limit value in order to visualise the entire distribution of
values.
A secondary conclusion from this study arose as a result of our having provided ROIs as
a baseline comparison group, since ROI analysis is more common in PET imaging than
parametric approaches. As expected, ROI analysis exhibited higher reliability and better
repeatability, but the degree to which ROI analysis showed improvements over parametric
analysis was unexpectedly large. We therefore recommend the use of surface-based methods
for performing exploratory statistical parametric analysis of cortical regions, but only when
the use of ROIs is not appropriate (i.e. when the expected effects may not be restricted to the
anatomical boundaries of a ROI, and when no hypothesis can be made about their location).
Themes
Reliability
We used the ICC as a measure of reliability, as well as the related repeatability, to assess
the performance of each method. Reliability was therefore the primary outcome measure for
comparison of the performance of the different techniques.
Replicability
In this study, we performed a replication of the results of Greve et al. (2014)40, using a different
PET camera, a different PET tracer, a different kinetic model, as well as a different protocol
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for the volumetric methods (which we believed might improve the performance of volumetric
methods relative to surface-based methods). We successfully replicated the previous findings,
despite the differences between the studies, suggesting that these previous findings are not
only replicable, but also generalisable (as described in Figure 1.9)100.
Reproducibility
This study constituted a valuable learning experience in reproducibility, as the processing
pipeline required switching several times between the use of R and MATLAB, but these two
were never integrated. However, after reviewers requested that we analyse the whole cortex
as opposed to just the frontal cortex as we had originally, this could be achieved in a matter
of days, as all steps following definition of the ROIs could be run from their scripts, and all
graphs and figures were automatically created and added to the manuscript. This study was
reproducible in parts, and this resulted in a great deal of time saved. The data and code were
not, however, shared.
4.2 Study II: Reliability of [11C]SCH23390 binding using
different image processing methods
There exist an very large number of different methods for image processing of neuroimaging data
which both can be, and are, applied, which limits the generalisability of findings102,104. In this
study, we aimed to study whether the use of automated and manual ROI delineation methods, as
well as frame-by-frame realignment for movement correction, altered the test-retest repeatability
and reliability of BPND measured using [11C]SCH23390. Automated ROI delineation methods
have the advantage of being less time-consuming to apply, and theoretically unbiased, while
manual ROI delineation should theoretically be more accurate, but has the possibility of being
biased. Frame-by-frame realignment has the advantage of reducing the influence of small
movements during the PET measurement, however it does involve reslicing each frame of the
PET measurement, which induces a small degree of smoothing. For this reason, with young,
healthy individuals who do not move greatly, it is possible that the process of performing the
realignment of frames could introduce more noise than the small movements themselves do.
We found that frame-by-frame realignment resulted in higher BPND values as well as
improvements in repeatability and reliability. Delineation of target ROIs using automated
delineation methods resulted in lower BPND due to the ROIs being larger in size, however
automated delineation of target regions also resulted in slightly higher reliability in all
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regions, as well as lower COV. Furthermore, ROI sizes showed lower COV, indicating
greater consistency. Automated delineation of the reference region resulted in improvements
in repeatability and reliability, as well as slightly larger ROI volumes. Importantly, the
delineation of the reference region was performed not according to anatomical guidelines, but
rather with the best properties for quantification (see Definition of regions of interest within
the Materials and Methods chapter). All comparisons of reliability showed inter-regional
consistency of effects, but none were significantly different due to the large confidence intervals
around ICC estimates.
Similarity in ROI delineations was examined using the Jaccard index, defined as follows:
J(A,B) = |A ∩B||A ∪B|
In other words, the Jaccard index is equal to the volume where A and B intersect (i.e. the
number of voxels which belong to both A and B), divided by their union (i.e. the number of
voxels which belong to either A or B or both). Jaccard indices were high in the striatum,
however they were low in the cortical regions as well as in the cerebellum. The differences
within the cortex are explained by the fact that there is less agreement between exact definitions
of what constitutes the dorsolateral prefrontal cortex for example. The differences in the
cerebellum came about as a result of the automated method selecting more voxels within the
lateral extent of the cerebellum, and the manual delineation coming close to the occipital
cortex.
In conclusion, frame-by-frame realignment is important even in healthy control subjects,
and we recommend its routine application to all measurements in the absence of movement
correction prior to reconstruction. We further show that automated delineation shows greater
consistency of its delineation, does not decrease the reliability or repeatability, and may indeed
even improve them, and can be reasonably be relied upon to be less biased compared to
manual ROI delineation. In combination with the fact that automated delineation requires
substantially less researcher time, this method can be routinely applied instead of manual
delineation. However, for studies in which there are expected to be gross morphological
changes, the accuracy of automated delineation compared to manual delineation should be
evaluated prior to its application. Choice of delineation of the reference region improved
test-retest performance, presumably because of its caution by design: that it avoided regions
of the brain which might affect reliable quantification by wide margins. This represents a
promising approach for delineation of reference regions.
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Themes
Reliability
We used reliability and repeatability to assess the performance of each method.
Replicability
In this study, we examined the test-retest reliability of [11C]SCH23390, which has been
examined before237,238 in other studies, with slightly different image processing procedures,
as well as different PET systems. We were able to obtain outcomes in a similar range to
those of Hirvonen et al. (2001)237. Kaller et al. (2017)238 observed much higher reliability
in all regions, however the reason for this discrepancy appears to be the wide age range of
individuals included in this study. This increases the between-subject variation, and thereby
inflates the ICC values. Age can be incorporated as a regressor into ICC calculations, and in
the case of having a standard deviation of age of over 10 years, probably should have been. In
conclusion, however, in this study, I would consider our result to successfully replicate previous
observations.
Reproducibility
This study, and the reprocessing of this data, resulted in the creation of tools for reproducible
extraction and test-retest analysis which are currently publicly available in the KI PET Tools
(https://github.com/mathesong/kipettools) and the relfeas (https://github.com/mathesong/
relfeas) R packages respectively. This meant that all processing of data after image analysis
could be performed reproducibly through subsequent iterations, although the raw data was
not shared.
4.3 Study III: Reliability and validity of simplified ratio-based
methods of quantification for [11C]PBR28
Due to the fact that there is no reference region of the brain which is devoid of the translocator
protein (TSPO), kinetic modelling using the metabolite-corrected plasma as the input function
is considered to be the gold standard for [11C]PBR28. VT is the most commonly reported
outcome measure from this approach, however this outcome exhibits a large degree of inter- as
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well as intra-subject variability. This limits its sensitivity for the detection of effects in applied
studies. Furthermore, collection of arterial plasma data is expensive, difficult or can even not
be possible in some centres, or for some patient groups. For this reason, there is a need for
methods of quantification of [11C]PBR28 which do not require arterial sampling. These two
considerations have led some groups to propose, as well as to use, ratio-based methods for
quantification, i.e. the distribution volume ratio (DVR, V
target
T
V refT
) or the standardised uptake
value ratio (SUVR,
∫
SUV target∫
SUV ref
)169,239,240. These methods result in large reductions in both
inter- as well as intra-subject variability. In this study, we aimed to assess the extent to which
these ratio-based methods were reliable and associated with VT.
We focused on the frontal cortex as a representative target region (and exhibited correlations
greater than r=0.9 with all other regions for both VT and SUV). We showed high reliability
for VT and moderate to high reliability for SUVs in both high- and medium-affinity binders
(HABs and MABs). For ratio-based methods, we used two denominator regions: the whole
brain and the cerebellum. The reliability of SUVR was found to be moderate (≈ 0.75 on
average), while the reliability of DVR was poor (≈ 0.5 on average). SUVs were found to be
fairly highly correlated with VT (HAB R2=0.64; MAB R2=0.86). However, DVRs and SUVRs
showed little to no assoication with VT (all R2 ≤ 0.34 divided by genotype), with half of the
associations showing negative correlation coefficients.
We examined this association further by comparing VT and SUV values between ROIs to
examine the correlational structure of the data. All regions were highly correlated (all VT
R>0.95, all SUV R>0.92). This suggests that ROIs are highly associated with one another
on a pairwise level, but does not answer whether there is extra remaining information in the
data after taking the main component of variation out. We therefore performed principal
component analysis (PCA), a multivariate dimension reduction technique, to assess how much
of the variance was remaining in the data after removing the first major dimension of variance.
Using all six ROIs, the first component of the PCAs explained 98.7 and 99.4% of the total
variability for PET1 and PET2 respectively. This suggests that almost all variation in all
of the ROIs is explained by a single dimension of variance, and that almost nothing is left
afterwards. Furthermore, from the test-retest analysis, this amount of variance is within the
margin of test-retest error. This suggests that little to no biologically relevant signal likely
remains after dividing the signal originating in one region with another.
We conclude that even if VT is not a perfect outcome measure, if it is even at least moderately
associated with TSPO levels in the brains of healthy control subjects, then the validity of
ratio-based methods must be called into question. The poor reliability of the DVR provides
further evidence that most of this signal is attributable to noise. In fact, even if the DVR were
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Figure 4.3: Associations between frontal cortex VT and ratio-based outcomes, using the whole
brain and cerebellum as denominator regions. Dotted lines indicate repeated measurements.
to be shown to be a valid measure of TSPO binding, the poor reliability of this measure implies
that its utility would be questionable for comparing individuals. Lastly, we show why its
reliability is so poor: almost all signal across all six ROIs, including the denominator regions,
is attributable to a single dimension of variance with almost no residual signal remaining which
might be explained by anything else. This provides a reasonable explanantion for why the
outcomes of ratio-based quantification methods can primarily be attributable to noise. For
data for which blood data is not available, we recommend that the SUV (and not the SUVR)
might constitute a reasonably valid compromise outcome measure due to its high association
with VT as well as its reliability. However, the use of SUVs relies on the assumption of no
differences in radioligand delivery between groups, which cannot be safely assumed in patient
samples.
This study was limited by the fact that it was conducted in a sample of young, healthy
individuals. For this reason, no regionally-specific alterations in TSPO availability are expected.
The use of SUVRs and DVRs can certainly describe large, localised effects such as the incidental
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Figure 4.4: Interregional correlations of PBR28 VT and SUV. Values represent Pearson’s
correlation coefficients. Ellipses designate the magnitude and the direction of the correlation
values.
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finding observed in Kreisl et al. (2009)241. For other conditions for which the effects cannot
be assumed to be so large, or be assumed to be so local, significant equivalence should be
demonstrated for the denominator regions which has not yet, to our knowledge, been shown
in any study utilising these measures. Another concern is that of the reliability of the DVR:
even if equivalence can be shown for the reference region, the results of this analysis suggest
that the reliability of the DVR is insufficient for its application to answer clinical questions
with small effects. However, the utility of DVRs increases with increased effect sizes. This was
one of the primary motivations which led to Study V, where this question will be covered in
greater detail.
Themes
Reliability
We used reliability and repeatability to assess the performance of each outcome measure.
Replicability
In this study, we examined the test-retest reliability of [11C]PBR28 SUVs and SUVRs, which
have been previously examined240. We obtained generally similar reliability despite our using
a different, but more appropriate, variant of the ICC94. We also obtained generally similar
repeatability (measured using the absolute percentage difference) to those presented in the
erratum to this paper242. However, while we concluded that SUVR was likely not a particularly
useful outcome measure, Nair et al. (2016)240 performed power calculations suggesting that as
few as 3 individuals would be needed in a longitudinal (i.e. pre-post) study to detect a 5%
change in SUVR, with 90% power. While this was reported as being indicative of SUVR being
a useful measure, what was not reported was that this 5% change represents a Cohen’s D
effect size of over 6 due to the extremely low degree of inter-subject variance after division by
the denominator region. For comparison, an effect size of 0.8 is estimated for the increases
in presynaptic dopamine function in schizophrenia which have been replicated many times21.
We therefore do not consider an effect of this size reasonable, and do not consider this power
analysis to be indicative of great utility for SUVRs.
Although not the main outcome of this study, another test-retest study of [11C]PBR28 has
also been reported157. While the outcomes of the present study were very similar to Collste et
al. (2016)158, which is to be expected due to both studies using the same data, Park et al.
(2015)157 observed substantially better repeatability (i.e. lower APD, by approximately 50%).
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One potential reason for this is that their mean VT values are approximately 30% higher on
average, likely due to their use of motion correction prior to reconstruction.
Reproducibility
This study was completed in a completely reproducible fashion, with all figures and tables
generated programmatically from the original time activity curve data. Linked and executable
code and data in the form of a reproducible analysis report are shared online so that others
may download the materials, run it for themselves to assess the robustness of our conclusions
(https://github.com/mathesong/PBR28_RatioMethods).
4.4 Study IV: Diurnal and seasonal variation of the brain
serotonin system
Circadian and seasonal changes in physiology are vital for the survival of animals and plants
as they allow for physiological anticipation to the regular 24 hour day-night cycles of the
earth. These changes take place in every cell, and are orchestrated in mammals by the
master pacemaker, the suprachiasmatic nucleus (SCN). These rhythms are entrained to the
environment primarily through natural rhythms of light exposure243. Circannual (seasonal)
changes in physiology appear to have a circadian basis as a response to changes in day length244.
Disturbances in chronobiology are thought to be involved not only in seasonal affective
disorder245,246, but also in non-seasonal major depressive depression247,248. Furthermore, both
of these disorders have been shown to respond to chronotherapeutic treatments249–251. The
serotonin (5-HT) system has attracted significant interest both in circadian regulation, but
also in understanding mood disorders, and 5-HT concentrations have been shown to exhibit
circadian and seasonal variation in both animals252,253 and humans254,255. Even in plants,
serotonin and melatonin exhibit both diurnal and seasonal rhythms as a function of the
availability of solar energy256. Circadian and seasonal changes have also been observed in
5-HT1A receptor (5-HT1AR) and transporter (5-HTT) concentrations in animals257,258. Using
PET imaging, seasonal changes in 5-HT1AR259 and 5-HTT260–262 have been shown in humans,
but circadian changes have not been reported. In this study, we aimed to attempt to replicate
previous findings of seasonal changes in these proteins, as well as extend these findings to
examine diurnal changes.
We defined a multiple regression model incorporating age, season (i.e. daylength) and day
course (i.e. the fraction of the photoperiod which had elapsed at the time of PET) and applied
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this to data from three regions for each radioligand. For each radioligand, the ROIs included
the dorsal raphe nucleus (DRN) as well as two other sets of regions which were based on
results from previous papers ([11C]WAY100635: cortical and subcortical, and [11C]MADAM:
striatal and extrastriatal). For [11C]WAY100635, we successfully replicated previous findings of
increases in BPND in the summer months for both cortical and subcortical regions. Furthermore,
we observed a positive correlation between BPND and elapsed day course. For [11C]MADAM,
we could not replicate previous findings of lower binding in the summer months260,261 in any
region, however we did observe a significant decrease with day course in the DRN.
This study was limited by the fact that it was cross-sectional, and based on old data, and
we thereby did not have control over the distribution of times of measurement. The ideal
experiment would involve performing PET imaging at various times across the day and night
within the same individuals. However, this would also presumably require large samples as
these effects do not appear to be large.
In conclusion, it is important to consider the potential influence of physiological processes
such as circadian and circannual alterations on underlying biochemistry. These changes are
important both from the perspective of examining differences between individuals in the 5-HT
system as an experimental factor which should be considered, as well as for understanding
the biological role of 5-HT itself in both healthy ciradian and seasonal physiology, as well in
depressive disorders245–248,262.
Themes
Reliability
As discussed more in Study V, one of the assumptions made in assessing the reliability of
an outcome is that the underlying levels will remain the same from test to retest. Diurnal
variability in protein availability measured using PET has been observed for metabotropic
glutamate receptor subtype 5263, and preliminary diurnal fluctuations have been reported for
TSPO158. This poses an interesting edge case for the assessment of reliability in PET studies,
for which another ICC formula might be appropriate which additionally takes systematic
differences between the two measurements into account94.
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Replicability
In this study, we successfully replicated the results of Spindelegger et al. (2011)259, however
we were not able to replicate the seasonal changes in 5-HTT which had previously been
shown260,261. McMahon et al. (2016)262 suggested that this may have been a result of our
not having included the polymorphism in the serotonin-transporter-linked polymorphic region
(5-HTTLPR) in the model. We also suggested that this may be a result of low power, as we
only had access to a sample of 40 individuals for the [11C]MADAM analysis. It should be
noted that another longitudinal study examining 17 seasonal affective disorder patients and 23
healthy controls with low seasonality in both the summer and winter, showed that patients had
higher 5-HTT binding in the winter months compared to controls262. However this study also
observed lower 5-HTT binding in the healthy control group in the winter months compared to
the summer months, which is the opposite direction to previous findings. Future studies will
be needed to shed light on the nature, size and direction of any such changes.
Transparency Statement
This study was conducted at an early stage of the PhD learning process. There are therefore
several parts of the analysis which could have been conducted in a better manner now.
The plots in this paper make evident a significant issue of heteroskedasticity in the assessment
of the effects of day course on [11C]WAY100635 binding. The two individuals who appear to
be influential outliers were in fact twins, suggesting that their low values are likely to be due
to some other factor.
This analysis is only one from the garden of forking paths, and the other was not reported. We
had initially included all ROIs separately, and had reported assocations of [11C]WAY100635
BPND with the number of hours elapsed since sunrise (i.e. not the fraction), and of
[11C]MADAM with elapsed day course fraction. Based on reviewer comments about a problem
of multiple comparisons, we combined ROIs into larger regions. Because we believed that
the elapsed day course fraction was the more valid metric, we tested this first, and observed
significant associations for both tracers, and we therefore did not proceed to test the hours
elapsed since sunrise. However, as Gelman & Loken (2013)264 argues, the garden of forking
paths can be a problem even when there is no p-value fishing expedition, since if there were to
have been no result, then the expedition might have continued. It was likely only because the
value was significant that we did not continue to probe the data.
Three [11C]WAY100635 and one [11C]MADAM measurement were excluded from the analysis.
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Two of the [11C]WAY100635 measurements were excluded a priori, however the remaining
two measurements were excluded based on image artefacts which were only discovered due
to the values for the DRN lying far from the regression line. This does not mean that the
measurements were correct - they did contain image artefacts after all - but our having given
greater scrutiny to those measurements which did not conform to our hypothesis can be
considered to be a QRP.
A further issue is that of partial HARKing (Figure 1.7): in this study, we initially set out
to examine seasonality and the relationship of 5-HT proteins with measures of light assessed
using data from the Swedish Meteorological and Hydrological Institute. Examining circadian
changes was initially a secondary aim. Over the course of the investigation, this aspect of the
investigation grew more important, presumably as a result of its being more compelling based
on the data, but also perhaps as I learnt more about the biological basis of seasonality. To
separate these two after the fact is difficult due to hindsight bias.
4.5 Study V: We need to talk about reliability
Measuring and understanding the reliability of outcome measures is extremely important, as it
allows us to gauge whether the accuracy of our data is capable of meaningfully distinguishing
between individuals. Not accounting for the reliability of outcome measures increases the risk
of type II errors, or can be considered to increase the risk of type M (magnitude) and type
S (sign) errors265. Reliability of outcome measures is associated with degree of attenuation
of the expected effect size. For a technique such as PET, which is so expensive, it is vital to
have an estimate of the expected effect size in order to make an assessment of the feasibility
of a study to answer the specified research question with the given resources: failure to
account for these factors can result in large wasted costs as well as the exposure of research
participants to radioactivity unnecessarily. For PET imaging, reliability is typically assessed
using test-retest studies with young, healthy control subjects. However, as described before,
reliability is sensitive to the amount of variation in a sample, and this must be taken into
consideration when assessing whether a specified outcome measure is likely to be useful for
comparing individuals in a new sample. For example, this issue limited our interpretation
of the results of Study III, where we were unable to exclude the possibility that ratio-based
outcome measures which showed poor reliability in our sample of young healthy controls, may
indeed show good reliability in certain clinical samples. In this study, I describe a method
for how to extrapolate an approximation of reliability for new, different samples based on the
summary statistics of published papers, as well as step through five case studies to demonstrate
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how these calculations can be performed, as well as how reliability can, and should, be used in
the planning of new studies.
Because reliability is a function of the relative variance attributable to measurement error and
true inter-individual variance (equation 1.8), the reliability can improved either by reducing
the measurement error, or by increasing the amount of true inter-individual variation in the
sample. As a result, using an ICC value calculated for a small, uniform, test-retest sample, a
new ICC can be estimated for a new sample of individuals whose inter-individual variation is
higher, by substituting the variation of the new sample into the equation, and assuming that
the measurement error is constant between the studies. In fact, even if the measurement error
is expected to increase or decrease in the new sample, the extent to which this is expected to
occur can be approximated and incorporated into the expression (equation 4.1).
ICCNewStudy = 1− (ρ× σTRT )
2
σ2NewStudy
= 1 + ρ
2σ2TRT (1− ICCTRT )
σ2NewStudy
(4.1)
where ρ represents the error inflation factor, which is the multiplicative increase in expected
measurement error in the new study (i.e. ρ = 1 assumes equal error between studies). Using
this equation, we can thereby calculate the required standard deviation in a new sample which
would be required to reach a suitable level of reliability. If we know the required standard
deviation for this to be the case, we can calculated the size of the difference between the groups
which would be required between two groups (in the case of a t-test) for such a standard
deviation to be reached.
The relationship of effect sizes with the reliability of measurement can be described by the
equation 4.2 (which is often called Nunnally’s equation266, although it has a much longer
history)267,268.
rObsA,ObsB = rA,B ×
√
reliabilityA × reliabilityB (4.2)
This is demonstrated in Figure 4.5, which shows the attenuation of underlying effect sizes as a
result of stochastic variability in the measured outcome described by the reliability. In the
figure, I refer to the population effect size, which is the true effect size of the distributions
from which the individuals are sampled from, and the sample effect size, which is the effect
size obtained based on the sample obtained from the population.
Based on the instability of effect size estimates, as well as the degree to which individual
measurements are not representative of underlying reality with low reliability values, Nunnally
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Figure 4.5: Left: Measured values and their 95% confidence intervals are represented by the
small points and error bars. Underlying true values are represented by the larger points. Low
reliability within groups is increased for the total sample in a comparison, given a sufficiently
large effect size, due to the larger variance of the combined sample. Right: True underlying
effect sizes (Cohen’s D, left) are attenuated by measurement error (right). The population
(Popn.) effect size (ES) and sample ES are of the underlying distributions from which the data
are sampled and of the obtained sample respectively.
(1987)95 recommended a reliability of 0.7 as a default lowest acceptable standard of reliability
for scales used in basic research, and that 0.8 should be seen as adequate. For applied settings in
which important clinical decisions are made based on measured individual outcomes, he suggests
a reliability of 0.9 as a minimum and 0.95 as adequate, since even with a reliability of 0.9, the
standard error is almost a third the size of the standard deviation. These recommendations
were made referring to internal consistency in psychometric measurements though, and not
test-retest reliability. Traditional standards for test-retest reliability, on the other hand, have
been more liberal, with Fleiss (1986)96 suggesting that ICC values between 0.4 and 0.75 could
be considered good. These recommendations were made based on psychometric questionnaires,
for which individuals can be expected to change their opinions over time. For PET imaging,
this source of variation can, in most cases (although Study IV is a good example where this
might not strictly be true), be considered to be negligible. For this reason, I argue that the
recommendations of Portney & Watkins (2015)98 are more applicable to PET research due
to their closer correspondence with those of Nunnally et al. (1978)95 defined for internal
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consistency.
I will briefly cover the results of the case study examples. In example 1, I demonstrate how a
measure which showed unacceptable (0.32) test-retest reliability can be successfully applied in
a sample with higher inter-individual variation, for which it exhibits an estimated reliability
of 0.93. In example 2, I demonstrate how accounting for the (acceptable) reliability of two
measures during power analysis can nearly double the number of participants needed in a
study to test a specified relationship. This can be expected to render many studies incapable
of answering their research question with the available resources. Furthermore, this can
help researchers to avoid wasting resources, as these conclusions can be reached before even
beginning to conduct the study. In example 3, I show how large, robust within-individual
effects do not necessarily allow for the comparisons between individuals using these measures,
and how this can be approximated using measures of reliability and standard deviations from
summary statistics. In example 4, I show that high reliability does not imply sensitivity for
small proportional effects, and how it is helpful to consider effect sizes rather than percentage
changes. Finally, in example 5, I return to the question from Study III regarding how large the
differences would be required to be to render the DVR an effective comparison measure. I show
that, according to our data, for the DVR to reach the lowest acceptable reliability for basic
research according to Nunnally (1978)95 (i.e. 0.7), effect sizes would be required to be between
very large and huge269, and to reach acceptable reliability, would be required to be 25% larger
than the huge guideline. For such large effects, the more easily interpretable, and much less
controversial, outcome measure of VT will be more than capable of distinguishing between
groups, thereby rendering the DVR practically obsolete for between-groups comparisons.
An important divide between reliability and repeatability should be emphasised here: reliability
is a measure of the ability of an outcome measure to distinguish between individuals, while
repeatability is a measure of the ability of the consistency of an outcome measure across
repeated examinations within the same individual. Hedge et al. (2017)270 recently showed that
some of the most well-validated cognitive tasks, such as the Stroop or Go-NoGo tasks, despite
exhibiting extremely robust within-individual effects, showed extremely poor reliability for
inter-individual comparisons, primarily attributable to low variation. They note that these
characteristics can be traced to a common underlying characteristic of low inter-individual
variation. Historically there has been a separation of within- and between-individual research,
both of which have prioritised different aspects of the distribution of the outcome measures.
They recommend caution in the assumption that robust outcomes from one paradigm should
apply to the other, since, as a heuristic, the opposite is more often likely to be true (although
this can be the case with extreme differences both between and within individuals).
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In conclusion, this paper motivates the use of reliability for better prospectively gauging the
feasibility of performing new between-individual studies with the resources available. The
paper also describes a method for estimating reliability for new, different samples, based on
the reported summary statistics from previously conducted test-retest studies.
Themes
Reliability
This paper is centred around reliability, application of reliability for power analysis, as well as
estimation of reliability for new samples.
Reproducibility
This paper was written in an entirely reproducible manner, where any change in parameters
or in functions would be directly incorporated into the figures and into the text. The relfeas
R package which can be used to implement all of the functions described is available online
(https://github.com/mathesong/relfeas), and is accompanied by code to implement all of the
calculations made in all of the case studies.
4.6 Study VI: Serotonin 5-HT1A receptor binding and
self-transcendence
As discussed in the previous study, low between- and within-individual variability tend to be
beneficial for within- and between-individual study designs respectively270. The high degree
of inter-individual variability in neuroreceptor densities between healthy controls, both post
mortem, and later in vivo using PET, was initally seen as problematic for comparisons of
patient and control groups, since this diminished the power of PET for examining small
proportional changes in neuroreceptor concentrations between groups8. However, this also
presented an opportunity to examine the sources of this inter-individual variation. The study
of personality traits is, by definition, related to inter-individual differences in stable patterns of
behaviour, cognition and emotion. Coupled with the fact that these traits have shown a high
degree of heritability271, and are thought to be important predictors of psychiatric disorders
at their extremes272,273, the study of correlations between brain neuroreceptor densities and
personality traits has flourished8. Sample sizes, however, have tended to be rather small, and
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as such it is especially important that they are validated by replication. One highly influential
study within the field of brain neuroreceptors and their association with personality traits
is that of Borg et al. (2003)274, which found strong negative associations between 5-HT1AR
BPND measured with [11C]WAY100635 and the Self-Transcendence scale and its Spiritual
Acceptance subscale from the Temperament and Character Inventory (TCI)183. This study
was only conducted in fifteen men, however, and a previous replication attempt in a sample of
20 healthy controls (as well as 19 patients with major depressive disorder) did not find evidence
of this relationship. This previous study, used frequentist statistical methods to analyse this
relationship, which is not optimal for such an analysis due to the possibility of type M errors
in the original study265 which could lead to type II errors in the replication study.
We studied the relationship between 5-HT1AR BPND measured with [11C]WAY100635 using
a larger sample (50 healthy men) of similar age to the original study, collected using the
same PET camera as the original study, and using the same Swedish-language version of
the TCI223. We used replication Bayes Factors (BFs) to assess replication success, as well
as default BFs to assess the evidentiary weight of the new data as if the original study had
never been published. We used these methods to analyse our data, as well as to re-analyse the
results of Karlsson et al. (2011)275. Collectively, we showed moderate to strong evidence of a
failed replication in both data sets, as well as moderate evidence for no association between
the scales and [11C]WAY100635 BPND. Even where evidence did not meet the level defined as
‘moderate’69,276, it still favoured the null hypothesis in all cases.
We also re-examined the original study in more detail, taking into account the realisation in
recent years that statistical procedures which may previously have been considered acceptable,
are able to generate false-positives at a rate higher than most appreciated79. Using the positive
predictive value, a measure of the likelihood that a given research result is true given several
assumptions76,78, we arrived at a probability that the original finding was true of only 9%.
This assumes a large effect size (i.e. r=0.5)277, a pre-study odds of 10% which we believe to be
reasonable for studies of neuroreceptors in personality, and a type I error rate of approximately
0.5 (due to the 21 comparisons made, which we considered to be equal to approximately 10
independent comparisons).
In conclusion, we could not successfully replicate the findings of Borg et al. (2003)274, and
showed consistent evidence for there being no association between [11C]WAY100635 BPND
and these scales. We thereby consider that we successfully replicated the results of Karlsson et
al. (2011)275. While we cannot exclude the possibility that there is a true underlying effect
and that both latter studies did not detect it, this result is considered to be unlikely based on
the positive predictive value of this result. A more likely conclusion is either that the original
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study made a type I error, or that the original study made a very large type M error.
Themes
Replicability
This paper represents a direct replication of a previous published, and highly influential
result99. We show evidence for the original finding either being a false positive, or a substantial
overestimation of the true underlying effect size.
Reproducibility
The code used to calculate replication BFs as well as to reproduce the plots is provided openly
online (https://osf.io/x9gjj/).
4.7 Study VII: Translocator Protein in Patients With
Psychosis: A Meta-analysis
The results of studies of TSPO in schizophrenia and psychosis have been mixed. These studies
are limited, however, by their heterogeneity. Studies differed not only by the different tracers
used and the medication status of patients, but also by outcome parameters, and accounting
for genotype. As described earlier, since there is no region of the brain devoid of TSPO, kinetic
modelling using the metabolite-corrected plasma as the input function is considered to be
the gold standard. While VT was reported in some studies166–168,170, other reported outcome
parameters have included VS160, BPND (calculated using rate constants)161,165, pseudo-BPND
(using reference-tissue models and a pseudo-reference tissue)162–164, and the distribution volume
ratio (DVR)169. TSPO genotype is also critically important, as it induces large differences
between groups for second-generation tracers. The influence of genotype on the binding of
first-generation tracers is controversial, since in vitro studies have suggested no differences
between genotypes278, while in vivo studies have shown genotype effects in peripheral organs
of the body279.
A further limitation of these studies is their size: all of these studies making use of arterial
sampling, have been small (n<20 patients). None of these studies individually has more than
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40% power to detect a medium-sized effect (i.e. Cohen’s D=0.5). This severely limits the range
of effects which could be detected.
Meta-analytic models allow researchers to compare the results of several studies and to derive
a pooled estimate, which should hopefully be the best possible estimate of the underlying
truth. The assumption of this model, then, is that the separate effect sizes are approximations
of a single underlying ‘true’ effect size. However, when different studies have used outcome
measures whose reliability differs drastically, then the effect sizes using the low reliability
outcome measure can be expected to be underestimated267. The signal-to-noise ratio of the
first-generation tracer [11C]PK11195 is thought to be very low152,280, and all of the outcome
measures used in the above studies of schizophrenia patients have been shown to exhibit poor
reliability154. For this reason, studies using [11C]PK11195 should yield much lower estimates
of the effect size compared to second-generation tracers. We therefore aimed to restrict our
meta-analysis to studies employing second-generation TSPO radiotracers, making use of VT as
an outcome measure using metabolite-corrected arterial plasma as input function, and taking
TSPO genotype into account. While meta-analyses are usually conducted using aggregate
data (i.e. published effect sizes), we instead performed an individual participant data (IPD)
meta-analysis. This means that data was obtained from previous studies at an individual
participant level, which is considered to be the gold standard of evidence synthesis methods281.
This further meant that the study emplying DVR169 could be used, since we could request the
VT values which were used to calculate the DVR. This resulted in five studies which could be
pooled. All authors of these studies agreed to be a part of the study, and sent raw VT values
for the frontal cortex, temporal cortex and hippocampus, as well as age, Positive and Negative
Syndrome Scale (PANSS) scores, duration of illness and drug status (medicated, drug-free,
drug-naive) at the time of measurement.
Before receiving the data, we pre-registered an analysis plan. This means that we decided
on the precise statistical models which would be employed, how the model would be selected
for performing inference, as well as how the comparison would be made. We also made
this pre-registration plan publicly available in a version-controlled online repository, such
that all modifications can be associated with their date of implementation. We performed
standardisation (centring and scaling to have mean 0 and standard deviation 1) of VT values
within each genotype, within each study. This thereby adjusted VT values from each radioligand
and genotype into the same scale units (i.e. units of standard deviations, or in other words, into
units of Cohen’s D effect size) (Figure 4.6)). We performed the meta-analysis using Bayesian
linear mixed effects modelling. We compared four models of increasing complexity using
information criteria to select the model with the best fit to the data with which to perform
inference. Inference was performed using Bayes Factors to compare the relative likelihood of
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Figure 4.6: Left: VT values from each of the constituent studies, shown separately for high- and
medium-affinity binders, for the frontal cortex (FC), temporal cortex (TC) and hippocampus
(HIP). Right: Standardised VT values after pooling.
the data under each of three hypotheses: 1) no effect, 2) higher TSPO binding in schizophrenia,
and 3) decreased TSPO binding in schizophrenia. We defined the hypothesis using half-normal
priors over the difference between patients and controls with a medium expected effect size
(Cohen’s D=0.5) defined as the standard deviation.
We found that the simplest model was preferred, i.e. the model which assumed that all effect
sizes from all studies and from all genotypes came from the same distribution. Performing
Bayesian hypothesis testing using this model, we showed extremely strong evidence for decreases
in TSPO levels compared to increases (decreases over 400 times more likely for all three regions),
and strong evidence for decreases compared to the null hypothesis (decreases over 30 times
more likely for all three regions). Performing subsequent parameter estimation, we showed
that the posterior distribution was centred around a moderate effect size (≈ 0.5), although its
credible intervals ranged between small and large. We also examined the effect of medication,
the association between binding and symptom scores as well as duration of illness. The
78
Figure 4.7: Standardised differences in TSPO VT between patients with psychosis and healthy
control subjects. For each study, the posterior probability density is shown in blue, the thick
line depicts the 95% credible interval, with the black circle depicting the posterior mean (also
written to the right of each plot). The cross and the thin line represent the raw patient-control
mean difference and its 95% confidence interval for each study.
posterior probability densities showed that these factors had little to no effect on measured
TSPO binding.
In summary, we showed strong evidence for decreases in TSPO binding in schizophrenia.
This is contrary to the original hypothesis of higher TSPO binding in patients compared to
controls. There has been extensive evidence for increases in pro-inflammatory markers in
schizophrenia patients142,282, and these results appear to contradict these findings. However, a
recent translational study showed that increases in pro-inflammatory cytokines were associated
with lower TSPO expression in the same regions of the brain283. Microglia and astrocytes,
both of which contain TSPO, can exist in both pro- and anti-inflammatory states, and in
vitro studies suggest that the pro-inflammatory macrophages and microglia may in fact be
associated with lower TSPO expression in humans284,285. TSPO may, therefore, not be an
exclusively pro-inflammatory marker in the human brain, and the lower levels reported may
indicate a compensatory mechanism for a pro-inflammatory state, altered function of glial
cells, or reduced density of immune and glial cells. In any case, regardless of the direction of
change, TSPO binding appears to systematically differ between schizophrenia patients and
controls, providing further evidence for the immune hypothesis of schizophrenia.
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Themes
Replicability
This study set out to aggregate data over all of the previous studies corresponding to the
inclusion criteria to arrive at the conclusion most supported by the sum total of the data. In so
doing, we replicated previous results showing decreases170, failed to replicate previous results
showing increases169, and observed an effect size which none of the previous studies were
adequately powered to detect. This suggests that the studies which did not find significant
differences can be considered to be indicative of insufficient evidence, rather than evidence of
absence of an effect. Furthermore, we pre-registered our analysis plan in order to minimise
the potential influence of biases, which have been associated with poor replicability77,84,85.
A recent paper explains that meta-analyses are particularly susceptible to these biases, as
subtle changes to inclusion criteria can have large consequences, and that for this reason,
preregistration of meta-analytic protocols is arguably even more important than it is for clinical
studies286.
Reproducibility
Although it was not possible to share the VT values which were used for the study, all code
used to perform the analysis is uploaded to a public repository to ensure transparency. This
includes the code used to query PubMed for the relevant articles and the specific search terms,
to perform the analysis, as well as to generate all the figures in the paper is openly provided
online (https://github.com/pontusps/TSPO_psychosis).
4.8 Study VIII: Delusional ideation and D1 receptor
availability
PET studies comparing dopamine D1R levels between schizophrenia patients and controls have
been inconclusive, showing higher levels127,130,131, lower levels126,129,132, and no difference128
in levels of D1R in the frontal cortex. As discussed in the introduction, these studies have
been limited by small sample sizes, and hence low statistical power, but interpretation of these
studies have also been complicated by several important differences between studies. These
include different tracers, different populations, duration of illness, but also, most importantly,
medication status. In vitro studies suggest that exposure to antipsychotic medication may
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result in decreases in D1R availability133,134. For this reason, it is important to study the
differences in D1R availability at early stages of the illness, before antipsychotic treatment, or
preceding its onset in order to understand its relationship to the disorder. In this study, we
investigated the latter question.
We examined delusional ideation as a measure of psychosis proneness as described in the
introduction. In order to make use of already collected PET and psychometric data, we
developed a new scale for delusional ideation using items from the self-transcendence subscale
of the TCI183. This scale was constructed using previously collected data from participants
who did not undergo PET. In order to make use of already collected PET data, we contacted
previous participants who had undergone PET with [11C]SCH23390 in previous studies by
letter and asked them to complete the 21 item version of the Peters Delusion Inventory (PDI)
scale171,172 online. And we also acquired new PET measurements with [11C]SCH23390, and
asked participants to complete both scales. As a result, this study made use of data collected
from three separate cohorts of individuals, from four separate data collections. We divided
this study into an exploratory, i.e. hypothesis-generating, component and a confirmatory,
i.e. hypothesis-testing, component84,85.
In the exploratory analysis, we successfully created a new scale for delusional ideation from
items of the TCI self-transcendence subscale with adequate reliability (Cronbach’s α=0.76).
We called this scale the TCI-DI (delusional ideation) scale. We then assessed the correlation of
this scale with PDI scores in individuals who completed both scales. The two scales were highly
correlated (Pearson’s R=0.64), thereby demonstrating convergent validity. Next, we aimed to
assess the relationship between this scale and [11C]SCH23390 BPND in the previously collected
data. This data contained individuals with a bimodal age distribution, males and females, and
there were originally two versions of the TCI-DI scale. Choosing one optimal analysis strategy
was not possible, and would be essentially random (e.g. inclusion of old individuals versus
inclusion of age in the regression model). For this reason, we used a multiverse analysis224, by
which all outcomes from all potential reasonable analysis decisions were presented in order
to increase transparency as well as minimise the influence of the garden of forking paths264.
From this analysis, we showed that all analytical approaches resulted in a negative association
between TCI-DI scores and [11C]SCH23390 BPND in both the DLPFC and the striatum.
In the confirmatory analyses, we first performed a replication study of our exploratory findings.
For this, we used the replication BF (as employed in Study VI), with which we obtained
moderate and strong evidence in favour of the null hypothesis in the DLPFC and striatum
respectively. Next, we applied Bayesian hypothesis testing to compare the likelihood of
hypotheses of a positive and negative association of [11C]SCH23390 BPND with PDI scores
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(i.e. increases or decreases in D1R availability with increasing delusional ideation). We made
use of regularising, zero-centred prior for the main effect of interest, and defined informative
priors derived from the literature to account for the effects of age on both [11C]SCH23390
BPND and PDI scores. This analysis showed that the data were 5 to 10 times more likely to
have occurred under the null hypothesis than either the increase or decrease hypotheses in
the DLPFC. Similar results were observed in the striatum. In the final substudy, we fit the
same model in a new sample, using the posterior probability destributions from the previous
comparison as priors to obtain updated estimates of the size of the effect. This data brought
parameter estimates even closer to zero for the association between [11C]SCH23390 BPND and
PDI scores. A 5 point difference in PDI scores has previously been found to be the difference
between delusional patients and controls172. We showed that a change of this magnitude was
associated with a change in BPND of only 1.5% of the mean, whose 95% credible interval did
not exceed 8%. According to these estimates, a difference even of all 21 points of the PDI
scale would only be associated with a difference in BPND of 6.5%.
In conclusion, despite the promising results obtained from the exploratory analysis, we
conclude that there does not appear to be a linear association between D1R measured with
[11C]SCH23390 BPND and measures of delusional ideation. There are four primary potential
explanations for these findings, namely that i) there is no association between D1R and
psychosis, ii) the changes in D1R may only occur at the onset of the disorder, iii) that changes
in D1R availability may be associated with some other aspect of psychosis proneness, such
as genetic risk factors or other behavioural traits, or iv) that the association between D1R
levels and psychosis proneness is of greater magnitude for higher levels of delusional ideation
(i.e. the association is not linear).
Themes
Reliability
In this study, we created a new psychometric scale for assessment of delusional ideation from
items belonging to the TCI scale, and selected items to obtain a good balance of reliability and
face validity. We also used the PDI scale, which has previously been shown to be reliable172.
In each separate investigation using either of these scales, we assessed the reliability of the
measure in the specific sample, to make sure that it was capable of differentiating between
individuals.
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Replicability
In this study, we made use of both exploratory and confirmatory testing. Because exploratory
investigations are prone to both false positives and overestimation of effect sizes, we made use
of a confirmatory replication analysis to assess the veracity of these findings. The replication
analysis, along with the remainder of the confirmatory analyses performed, suggests that the
original exploratory findings were likely to have been a false positive.
Reproducibility
Although it was not possible to share the TACs or BPND values which were used for the study,
all code used to perform the analysis is uploaded to a public repository to ensure transparency.
Transparency Statement
It is noteworthy that the exploratory finding of a negative association between TCI-DI scores
and [11C]SCH23390 BPND, despite our transparently reporting the full extent of the multiverse
analysis, did not cover the entirety of the true multiverse. As mentioned in the manuscript, it
was already known that the whole Self-Transcendence scale was associated with [11C]SCH23390
BPND in this sample based on the results of a previous masters thesis which examined the
relationship of BPND with all scales of the TCI. This study was performed independently of
the original study: we only examined the TCI-DI scale in this particular investigation, with
selection of items from this scale performed blind to the results of the previous study, and
the image analysis and quantification were performed using more advanced tools and different
regions of interest. However, it is nonetheless highly probable that both the questionnaire
and the binding potential values tested in this study are fairly highly correlated to the values
tested before.
This is an important consideration, and especially for expensive methodologies such as PET:
exploratory investigations can diminish the inductive “value” or “potential” of a data set, even
for subsequent studies. As described in the introduction, a p value is essentially a measure of
surprise given an assumption of the null hypothesis being true. Surprising outcomes become
less surprising with more opportunities to exhibit unusual behaviour (i.e. error rates increase),
and correction for multiple comparisons is an important safeguard against this. Similarly,
multiple analyses of the data as it is collected to decide whether to halt or continue data
collection must be corrected for using sequential analysis methods as this may also increase
the error rate287. However, when different investigators examine the same data from different
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perspectives, it is not entirely clear how these multiple comparisons should be corrected for.
Previous comparisons of similar, but not identical, data do allow investigators some insight into
which comparisons will yield the most “surprising” outcomes in subsequent studies. Caution
is therefore warranted in embracing exploratory research practices, since it decreases the
subsequent inductive value of a data set for later hypothesis-driven research.
4.9 Study IX: Dopamine D1 Receptor Availability in
First-Episode Neuroleptic-Naive Psychosis Patients
As discussed in Study VIII, the inconsistency in the results of PET studies investigating the
D1R in schizophrenia may be due to various confounders, among which the most important
is thought to be medication. This is due to in vitro findings showing that antipsychotic
medication may decrease levels of D1R in the prefrontal cortex133,134. For this reason, we
suggest that it is important to study differences in D1R availability either at early stages of
the illness, before antipsychotic treatment, or prior to disease onset. While we studied the
latter question in Study VIII, in Study IX, we aimed to investigate the former
In this study, we compared [11C]SCH23390 BPND measured in the DLPFC and striatum
between 18 drug-naive first-episode psychosis patients and 17 healthy controls. This constitutes
the largest sample size of drug-naive patients examined for D1R availability using PET. Based
on the previous results in the literature, we hypothesised that the patients should exhibit
higher D1R availability in the DLPFC compared to controls. We used both classical frequentist
testing as well as Bayesian hypothesis testing to compare the groups. For the latter, we made
use of informative priors for the effects of age on [11C]SCH23390 BPND based on previous
studies, and used zero-centred regularising priors over the effects of patient status. Specifically,
for the regularising priors, we used the expected effect size as the standard deviation of
half-normal distributions for the hypotheses of higher, and lower levels of D1R availability in
patients compared to controls. In this way, we could compare both of these two hypotheses
with the null hypothesis as well as with one another.
The collection of this data was performed over 14 years, and hence there was some degree of
heterogeneity in the measured data itself. A central part of this analysis was therefore testing to
make sure that these differences were not acting as confounders, and accounting for the factors
which might. Differences included aspects of PET acquisition (e.g. 2D and 3D acquisition,
different measurement lengths, or some participants leaving the camera prematurely), PET
reconstruction (filter settings), structural MR (T1- or T2-weighted sequences), the potential for
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unconscious bias in manual ROI delineation, data storage (different file formats representing
data in 2 or 3 dimensions and may impact quantification), as well as biological factors (age
and sex of participants). For testing these factors, we made use of equivalence testing68.
Almost all factors were confirmed not to have large effects on BPND values. PET acquisition
in 2D or 3D could not be shown not to impact the results, and so we resolved to test the
association both with and without the two measurements acquired in 3D mode. While we
observed a significant age × sex interaction in this data, we were able to show in two other
[11C]SCH23390 datasets288,289 that this association was not significant. This suggests that the
observed association was more likely to be a false positive result. Following this preliminary
analysis, we defined i) calibration factors for measurements shorter than 51 minutes and
removed frames from longer measurements, ii) a calibration factor for one measurement with
low molar activity and high injected mass, iii) the statistical model as a multiple regression
with [11C]SCH23390 BPND and age and patient status as independent variables.
In contrast to our hypothesis, we observed a statistically significantly lower [11C]SCH23390
BPND in the DLPFC of psychosis patients compared to healthy controls (Figure 4.8). The
null hypothesis could not be rejected in the striatum. In the Bayesian analysis, we found
that the data was 3.7 times more likely under the decrease hypothesis compared to the null
hypothesis, indicating moderate evidence for decreases in the DLPFC. However, the data was
substantially more consistent with the decrease hypothesis than they were with the increase
hypothesis (over 50 times). For the striatum, the null hypothesis was favoured over both of
the other models (by 3 and 8 times for the decrease and increase hypotheses respectively). We
can therefore conclude that we observe a regional effect since we show moderate evidence of
an effect in the DLPFC, and moderate evidence of no effect in the striatum. We also showed
that exclusion of the measurements collected in 3D did not alter the outcomes.
A significant caveat of this study, and indeed of any PET studies investigating D1R availability
in the cortex, is that a non-negligible proportion of the binding is attributable to 5-HT2A
receptor binding; approximately 25% of cortical [11C]SCH23390 or [11C]NNC112 binding.
While some studies have suggested that 5-HT2A receptors may be decreased in schizophrenia
patients compared to controls290,291, the literature has not been consistent292–295. However, if
the observed decreases were to be entirely explained by decreased 5-HT2A receptor binding,
their magnitude would imply that the availability of 5-HT2A would need to be decreased by
50%, which is much larger than the reported decreases. We therefore conclude that this is
unlikely to fully explain the observed lower BPND in patients.
Importantly, despite the result being significant in the frequentist analysis and the hypothesis
supported by the Bayesian analyses, the magnitude of the result is not so compelling. An
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Figure 4.8: Standardised residuals representing the difference between healthy controls and
psychosis patients after correction for the effects of age. Significant differences were observed
in the dorsolateral prefrontal cortex (DLPFC).
analysis of the effect size in the frequentist analysis reveals that the effect size is centred
over a medium effect size277, but that the 95% confidence interval surrounding this effect size
ranges from very small to very large269. Similarly, the effect in the striatum, despite not being
significant, has a confidence interval which encompasses both a large negative effect as well as
moderate positive effect. From the perspective of the Bayesian analysis, an interpretation of
the BF of 3.7 as posterior model odds means that the study provides insufficient evidence to
persuade someone who believed a priori (i.e. prior model odds) that the null hypothesis was 4
or more times more likely, to qualitatively change their beliefs.
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Themes
Replicability
This study set out to replicate previous findings of differences in D1R binding between psychosis
patients and controls. Based on our interpretation of literature, we considered the results of
Abi-Dargham et al. (2012)130 to be most compelling due to their comparatively large sample
size, and to their sample most closely resembling our own sample, with a group of drug-naive
patients. In this sense, we failed to replicate these findings, observing an effect in the opposite
direction, and obtaining strong evidence that the decrease hypothesis is more likely given our
data.
Reproducibility
All modelling and analysis was performed in a reproducible report. When the article is
submitted, all analysis code will be made available online to accompany the article for
transparency.
Transparency Statement
It is worth noting that a previous exploratory analysis of this data was conducted following
collection of the data, but without the calibration factors or the confounder analyses, as well as
without motion correction performed in this study. The previous analysis yielded no significant
results, and a parametric analysis revealed potential decreases in the anterior cingulate cortex
at an inappropriately high alpha level. The present analysis was performed completely blind
to the results of the previous analysis, and we do not consider the previous results to have
influenced this analysis.
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Chapter 5
Future Perspectives
PET is an powerful methodology capable of deriving insights not possible with other in vivo
imaging techniques. It is also, however, a very expensive method which additionally requires
exposure of participants to radioactivity and sometimes also to arterial cannulation. It is
therefore of both scientific and ethical importance that PET measurements are utilised to
their full potential. This is, unfortunately, not currently the case. Most studies using PET are
small: while some research questions only require very small sample sizes, many important
questions for understanding the neurochemical basis of especially psychiatric disorders will
require ever larger samples for deriving meaningful conclusions to advance our understanding.
Another issue is that of clinical studies making use of tools, methods or outcome measures
which have not been sufficiently evaluated. Both of these issues, in combination with poor
application of statistical testing procedures, give rise to mixed results in many fields of clinical
PET research, resulting in poor replicability and generalisability of findings. Of couse, this
is not unique to PET research: failure to replicate is a substantial problem in biomedical
science as a whole58,59, and questionable research practices79,86 and underpowered studies78
are common across different fields of study. However, in recent years, a number of potential
solutions have been gaining in popularity, primarily centred around an increasing the openness
and transparency of research.
While assessment of the replicability of findings is the gold standard by which the veracity of
conclusions can be evaluated, computational reproducibility serves much of the same purpose,
by allowing others to see all steps taken and to determine their degree of reasonableness and
correctness, but at a fraction of the cost. Additionally, when the data is provided alongside the
code, other researchers are even able to assess the sensitivity of reported findings to differences
in how the data may have been processed101. This serves as a safeguard against potentially
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harmful errors107,109.
Transparency at the level of the final analysis, however, may not capture the full degree of
analytical flexibility, whether or not it may have been conscious. An important safeguard
is that of pre-registration, namely recording how the data will be processed as well as the
hypothesis being tested and how this will be achieved84. In this way, researchers can both stand
by the hypotheses made prior to data collection, as well as be conscious of which hypotheses
arose from observation of the data, what Nosek et al. (2018)84 refers to as postdiction (as
opposed to prediction). Of course, studies may still be conducted in a sub-optimal manner, but
it still increases the statistical trustworthiness of claims made by knowing what was originally
planned.
An extension of this idea is that of Registered Reports: that scientific manuscripts are
submitted to journals consisting only of the introduction and methods, before any data has
been collected296. This allows reviewers to critique the methods of a study prior to its inception,
and thereby both provide helpful feedback to authors thereby limiting the potential for mistakes
to be made during study design, but also to assess the scientific importance of the research
question rather than the results. If the article is accepted, the journal makes a commitment
to publish the final paper provided that the study is conducted as planned and that the
conclusions are reasonable. This is assessed during a second round of peer review during which
the results and discussion sections, containing the results of the pre-registered analyses as
well as any additional unregistered analysis, are evaluated. This thereby reduces the positive
bias observed in the literature since the incentives for authors change from producing the
most compelling story to producing the most accurate one296–298. This further protects both
authors and reviewers from bias on the part of the other. At the time of writing, there are
currently 141 journals offering Registered Reports as a publishing format (https://cos.io/rr/).
While of course there is also a need for exploratory research, shifting the balance in favour
of confirmatory research is an important part of improving the replicability of research and
thereby the generalisability of findings85.
Reducing the degree of bias in the literature and improving the replicability of individual
research findings is an excellent start, but there remains the issue that PET research is so
expensive that sufficiently large samples to answer research questions in a robust manner
are rare. Psychiatric PET research is therefore likely to be particularly affected by low
statistical power as described in the Introduction section. For example, in Study IX, despite
our examining the largest single sample of drug-naive schizophrenia patients, the precision of
the effect size estimates were insufficient to determine whether the effect was very large or
very small (i.e. 58% compared to 98% group overlap). The only solution to this widespread
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issue is that of collaboration between research groups and data sharing. An example is Study
VII, for which all of the individual studies did not even have 50% power to detect the final
meta-analytic effect size, but when the data was combined, the conclusions were clear. The field
of genetics openly embraced this strategy, where open data sharing and consortia have become
central tenets, and this has yielded great dividends299. The neuroimaging community more
broadly has begun to move in this direction with OpenfMRI300, now renamed to OpenNeuro301,
functioning as platforms for sharing data.
Data sharing and collaboration through these platforms have also given rise to a new standard
structure for sharing neuroimaging data, called the Brain Imaging Data Structure (BIDS)103.
With a unified structure for storage of neuroimaging data in place, this has led to the
development of BIDS Apps302. These are standardised neuroimaging pipelines which can
digest and ‘understand’ the content of a data set, and thereby process this data without
requiring substantial setup or adjustment. They do not even require installation, and run
across all operating systems, due to their operating within Docker containers303. This also
dramatically simplifies the issue of data pooling, since generalisability is diminished by the wide
variety of different processing pipelines used to analyise data between research groups102,104,302.
Re-processing multiple datasets in a homogeneous manner is rendered a substantially less
demanding task when all data is stored and processed in the same manner. This is also a
good real-life example of the theoretical benefits which are often proposed to result from an
increased focus on reproducible research practices106. While PET may be lagging behind other
neuroimaging methods in its adoption of these principles, the first PET BIDS datasets have
been made available on OpenNeuro, and the first PET BIDS app, APPIAN, was recently
released304. The BIDS and BIDS app framework should also pave the way for more advanced
methods for image analysis and quantification of PET data to be more accessible for more
research groups which lack software engineering expertise, and will simplify reproducible
reporting of research findings.
In summary, I believe these initiatives to increase the transparency and openness of biomedical
science can be of tremendous benefit for the research community. Greater adoption of these
practices will hopefully improve the replicability of clinical PET research, but also accelerate
the development, application and transmission of new and improved research methods.
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